Accepted Manuscript 2-Aminothiazole Derivatives as antimycobacterial agents: Synthesis, characterization, in vitro and in silico studies Parameshwar Makam, Tharanikkarasu Kannan PII:
S0223-5234(14)00914-3
DOI:
10.1016/j.ejmech.2014.09.086
Reference:
EJMECH 7394
To appear in:
European Journal of Medicinal Chemistry
Received Date: 21 February 2014 Revised Date:
21 June 2014
Accepted Date: 9 September 2014
Please cite this article as: P. Makam, T. Kannan, 2-Aminothiazole Derivatives as antimycobacterial agents: Synthesis, characterization, in vitro and in silico studies, European Journal of Medicinal Chemistry (2014), doi: 10.1016/j.ejmech.2014.09.086. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
Graphical abstract 2-Aminothiazole derivatives as antimycobacterial agents: Synthesis, characterization, in
TE D
M AN U
SC
RI PT
vitro and in silico studies
A library of 2-aminothiazole derivatives were designed, synthesized and evaluated against
AC C
EP
Mycobacterium tuberculosis, H37Rv.
ACCEPTED MANUSCRIPT 2-Aminothiazole derivatives as antimycobacterial agents: Synthesis, characterization, in
2
vitro and in silico studies
3
Parameshwar Makam, Tharanikkarasu Kannan*
4
Department of Chemistry, Pondicherry University, Puducherry-605 014, India.
5
*
6
E -mail address:
[email protected];
[email protected] 7
Abstract: A series of 2-aminothiazole derivatives with a wide range of substitutions at 2-, 4-
8
and 5- positions were designed and synthesized using Hantzsch thiazole synthesis. These
9
compounds were evaluated for their inhibitory potential against Mycobacterium tuberculosis
10
(Mtb), H37Rv. The compound, 7n showed high antimycobacterial activity with MIC value of
11
6.25 µM and the succeeding compounds, 7b, 7e and 7f also exhibited antimycobacterial
12
activity with MIC value of 12.50 µM. Docking studies of these molecules with β-Ketoacyl-
13
ACP Synthase (KasA) protein of Mtb have been carried out to understand the mechanism of
14
antimycobacterial action. The compound, 7n showed good interaction with KasA protein
15
with the Ki value of 0.44 µM.
16
Key words: Mycobacterium tuberculosis; tuberculosis; 2-aminothiazole; drug like molecule;
17
β-Ketoacyl-ACP Synthase; docking studies
EP
TE D
M AN U
SC
Corresponding author. Tel: +91-413-265 4708; Fax: +91-413-265 6740.
AC C
18
RI PT
1
1
ACCEPTED MANUSCRIPT 19 20
1. Introduction Tuberculosis (TB) is one of the world’s leading airborne contagious diseases that is mainly caused by Mycobacterium tuberculosis (Mtb), a species of genus Mycobacterium.
22
According to the eighteenth global TB report of the World Health Organization (WHO), it
23
was estimated that 1.3 million people died out of 8.6 million new infections in 2012 [1].
24
Although the death rate declined 45 % between 1990 and 2012, TB is next only to HIV/AIDS
25
in killing the highest numbers of people through single infectious disease. Whilst TB is an
26
ancient disease, its pathogen, Mtb was discovered in 1882 and the chemotherapy for this
27
disease was started in 1944 using streptomycin [2]. In the following years, the first line drugs
28
such as isoniazid, ethambutol, rifampicin, etc., and the second line drugs such as
29
ethionamide, p-amino salicylic acid, cycloserine, kanamycin, etc., have been used to treat TB
30
either independently or in combination with other drugs [3]. But, after 1950s, the rate in
31
developing novel and effective drugs was slow [4-6]. As a result, there is no sufficient
32
number of anti-tuberculosis drugs in the market. Due to this, TB patients still depend on the
33
drugs discovered in 1950s [7]. In addition, the constant emergence of multi, extensively and
34
totally drug – resistant strains of Mtb, and close synergy with HIV/AIDS [8] have made the
35
goal of wiping out TB from this world difficult. Poverty, complexity of the disease,
36
prolonged and poor administration of drugs are added reasons for the resurgence of TB as the
37
major global health burden [9-12], particularly in high TB burden countries [13].
39
SC
M AN U
TE D
38
RI PT
21
To find out a solution to this alarming increase of TB infections, many attempts have been made to understand the reasons behind the evolution and existence of resistant strains of
41
Mtb [14-16]. On the other hand, the generation and high-throughput screening of large
42
chemical entities with a wide spectrum of known and novel scaffolds have also been carried
43
out to identify lead anti-TB molecules with high efficacy, unique and novel mode of action.
44
[7, 17-20]. Among the diverse and medicinally relevant scaffolds, 2-aminothiazole
45
derivatives have exhibited good activity against Mtb, H37Rv [17, 21, 22]. Interestingly, 2-
46
aminothiazole derivatives are found to be structurally similar to thiolactomycin (TLM) [23] ,
47
a β-Ketoacyl-ACP Synthase (KasA) protein inhibitor [24]. TLM inhibits the biosynthesis of
48
mycolic acid, an essential cell wall component of Mtb, by inhibiting KasA protein [25].
49
Hence, it is expected that 2-aminothiazole derivatives may also inhibit growth of Mtb by
50
inhibiting biosynthesis of mycolic acid. 2-Aminothiazole derivatives have been validated
51
recently against UDP-galactopyranose mutase thwart to inhibit Mtb and found to have
AC C
EP
40
2
ACCEPTED MANUSCRIPT improved activities more than their parent thiazolidinone derivatives [26]. Nitazoxanide [27,
53
28], 2-aminothiazole-4-carboxylates and 2-amino-4-(2-pyridyl) thiazoles are other molecules
54
of this class now in clinical evaluations [19]. In addition to these, 2-aminothiazole scaffold is
55
attracting medicinal chemists continuously by being an integral part of drugs which are in
56
clinical practice for the treatment against tumor and cancer [29, 30], hypertension [31],
57
inflammation [32], analgesics [33], hypnotics [34], schizophrenia [35], HIV/AIDS [36],
58
malaria [37, 38] and microbial infections [39], to mention a few.
59 60
RI PT
52
Limited exploration of 2-aminothiazole derivatives against Mtb and the possibility of generating novel and potent Mtb inhibitors from this class encouraged us. In our previous
62
studies, we have synthesized novel 2-(2-hydrazinyl) thiazole derivatives comprising 2-
63
aminothiazole scaffold and evaluated for their inhibitory potentials against Mtb, H37Rv [40]
64
and Plasmodium falciparum, NF54 [41]. The good results obtained in these studies
65
encouraged us to go on to synthesize novel 2-aminothiazole derivatives. Hence, in the present
66
study, novel 2-aminothiazole derivatives are designed with a wide range of substitutions at
67
2-, 4- and 5- positions and evaluated their inhibitory potentials against Mtb by in vitro assays.
68
In addition, with the help of ligand – protein interaction studies through docking studies, an
69
insight into the mechanism of action has also been carried out against KasA protein.
70 71
2. Results and Discussion
72
75
EP
74
2.1. Rational design
The physico-chemical properties play a vital role in defining drug like molecule
AC C
73
TE D
M AN U
SC
61
76
(DLM) character and pharmacokinetics properties such as absorption, distribution,
77
metabolism, excretion and toxicity (ADMET) of a molecule [42, 43]. Certainly, the necessary
78
physico - chemical properties and their importance in the early drug discovery are best
79
explicated by the works of Lipinski [44] and others [43, 45, 46]. These rules state that the
80
molecule with a molecular mass less than 500, Log P value less than 5, hydrogen bond
81
donors less than 5, hydrogen bond acceptors less than 10, polar surface area less than 140 and
82
the number of rotatable bonds less than 10 could be a molecule with DLM character.
83
3
ACCEPTED MANUSCRIPT 84
In our previous investigation, 2-(2-hydrazinyl) thiazole derivatives have been designed without violating rule of five and synthesized. The synthesized compounds have
86
been evaluated for their inhibitory potential against Mtb, H37Rv and found that some of these
87
compounds show inhibitory potential against Mtb, H37Rv. As most of the anti-TB and
88
antibacterial compounds are exceptions to the rule of five [20, 45], in the present
89
investigation, we intentionally increased the lipophilicity of 2-aminothiazole derivatives by
90
designing compounds with the Log P values beyond 5. While designing, the structural
91
features of reported anti-TB molecules have been considered as shown in Figure 1. An
92
expectation during the designing is that the molecules with a defined optimal range of the
93
lipophilicity could influence in identifying molecules with high therapeutic success by
94
monitoring the ADMET properties of the molecules [47-49]. Bedaquiline, the only anti-TB
95
drug that has been approved by FDA in the last 40 years for drug-resistant tuberculosis
96
treatment is also a lipophilic drug [20]. Hence, by considering the cell wall permeability and
97
the solubility, during designing of 2- aminothiazole derivatives, core 2-aminothiazole
98
scaffold has been retained and additionally, substituted phenyl, naphthalene and positional
99
isomeric pyridyl systems have been incorporated on either side of 2-aminothiazole, i.e., at
M AN U
SC
RI PT
85
both 2- and 4- positions of the thiazole ring to induce lipophilicity and hydrophilicity
101
correspondingly. In addition to this, the H at 5- position has been replaced with other
102
functional groups such as CH3 and Br to understand the effect of this position on
103
antimycobacterial activity.
105
The physico – chemical properties of the designed 2-aminothiazole derivatives have
EP
104
TE D
100
been determined and the results are summarized in Table 1. The data reveal that all the
107
compounds follow the Lipinski rule of five except Log P values. As mentioned earlier, Log P
108
values of N-phenyl thiazol-2-amine derivatives (7a-7e, 7g, 7i-j and 7q-7s) and N-2-pyridyl
109
thiazol-2-amine derivatives (8c-j) have been intentionally maintained higher than 5. In
110
addition to these, the other parameters such as polar surface area and number of rotatable
111
bonds are found to be in the range of 24.919 - 83.63 and 3 - 6 respectively that are in the
112
range of recommended values.
113 114
AC C
106
2.2. Synthesis of 2-aminothiazole derivatives
115 116 117
The designed 2-aminothiazole derivatives have been synthesized according to the synthetic pathways described in Scheme 1. First, arylthioureas were synthesized by refluxing 4
ACCEPTED MANUSCRIPT corresponding anilines with ammonium thiocyanate in the presence dil. HCl [50] as shown in
119
Scheme 1 (i). But, pyridyl thioureas could not be achieved with the same procedure and
120
hence, an alternative procedure was used [51]. In this procedure, first, 2-pyridylamine,
121
ammonium thiocyanate and benzoyl chloride were reacted in acetone to yield N-(pyridin-2-
122
ylcarbamothioyl) benzamide. This was further hydrolyzed with 10% NaOH solution to yield
123
the corresponding pyridyl thioureas [51] as shown in Scheme 1 (ii). The phenyl and the
124
pyridyl thioureas have been characterized by the spectral methods and the data were found to
125
be in good agreement with the literature data [50-52].
127
SC
126
RI PT
118
In the next step, pyridyl α-bromo ketones have been synthesized from corresponding acetyl pyridines [51] as shown in Scheme 1 (iii). Finally, the aryl or pyridyl thioureas have
129
been heterocyclized to thiazole by reacting with the aryl or pyridyl α-halo ketones in the
130
presence of ethanol using the classical Hantzsch thiazole procedure [51] as shown in Scheme
131
1 (iv). All the synthesized compounds have been characterized using nuclear magnetic
132
resonance (NMR), infra-red (IR) and mass spectroscopic techniques. The aromatic protons
133
present in the pyridyl and phenyl systems are observed at 6.5 – 9 ppm. The appearance of the
134
characteristic peak of thiazole ring H at around 6.50 ppm and the disappearance of the
135
characteristic peaks of reactants in the 1H NMR spectra confirm the formation of the thiazole
136
ring. The characteristic peak of the NH at the 2nd position of the thiazole ring resonates at
137
around the 10.5 to 12 ppm. Similarly, the precise matching of the experimental mass and
138
CHNS data with the calculated data further confirms the formation of analytically pure
139
desired products. All the synthesized 2-aminothiazole derivatives have been classified into
140
four groups based on the structural similarities of the substitutions at the 2nd and 4th positions
141
on the 2-aminothiazole scaffold as shown in Table 2. In the first class of compounds,
142
substituted phenyl ring systems are attached on both 2nd and 4th positions on the 2-
143
aminothiazole scaffold. The spectral data of the compounds, 7a [53], 7b [53], 7f [54] 7g [55,
144
56] and 7h [55] are in agreement with the literature reports. In the second class, the
145
substituted 2-pyridyl and phenyl systems are incorporated on the 2nd and 4th positions of the
146
2-aminothiazole scaffold respectively. Among this class of compounds, the compounds, 7l
147
[51], 7o [51, 55] and 7p [55] are reported and the data is in agreement with the reported
148
literature. Similarly, in the third class of compounds, substituted pyridyl and phenyl systems
149
are incorporated on the 4th and 2nd positions of the 2-aminothiazole scaffold respectively.
150
The fourth class of compounds includes substituted pyridyl systems on both 2nd and 4th
AC C
EP
TE D
M AN U
128
5
ACCEPTED MANUSCRIPT 151
positions of the 2-aminothiazole scaffold. The spectral data of the reported compounds, 8l
152
[57] and 8n [58] are in agreement with the literature.
153
155
2.3. Single crystal and crystal packing studies The spatial arrangement of the drug molecules is an important factor and its
RI PT
154
understanding is more helpful in designing and identifying the better hit and lead drug
157
molecules with enhanced biological activity [51, 59, 60]. The spatial arrangement of the
158
molecules in its stable conformation can be identified by the single crystal X-ray studies. The
159
present 2-aminothiazole derivatives contain commonly three aromatic cyclic systems in their
160
structures viz. substituted phenyl, thiazole and pyridyl systems. Hence, based on the structural
161
diversity of the molecules, 7g and 8l have been selected as the representative molecules of 2-
162
aminothiazole derivatives. The molecule 7g contains both phenyl rings attached to 2nd and 4th
163
positions of 2-aminothiazole ring and the molecule 8l contains both pyridyl rings attached to
164
the 2nd and 4th positions of the 2-aminothiazole scaffold. The single crystal structures and
165
crystal packing diagrams of 7g and 8l have been solved and the results are summarized in
166
Table 3.
168
M AN U
TE D
167
SC
156
The single crystal structure of 7g is represented in the ORTEP diagram with 40% ellipsoid probability and its crystal packing is depicted in Figure 2. The single crystal
170
structure reveals that 7g is stabilized by its monohydrate form i.e., solvation by one water
171
molecule. The alignment of the three planar rings of the molecule, the 4-methoxy phenyl ring
172
systems attached to 4th positions of thiazole ring and the 2-aminothiazole ring are oriented
173
almost in the same plane. Whereas, the 4-hydroxy phenyl system attached to NH of the 2-
174
aminothiazole ring is perpendicular to the 2-aminothiazole ring (Figure 2a). The single
175
crystals are oriented in the opposite directions i.e., head to tail dimer fashion and are
176
stabilised by inter molecular hydrogen bonds. There are two inter molecular hydrogen
177
bonding (2.284 Å, 159.98°) exist between -NH group present in the 2-aminothiazole ring of
178
one molecule and the N present in the thiazole ring of other molecule and vice versa. In
179
addition, π – π interactions also exist between two 4-hydroxy phenyl rings (2.844 Å, 2.915 Å)
180
present in 7g. The solvent, water molecule is sandwiched between the two 7g molecules and
181
it is stabilising the packing of the crystals by forming four inter molecular hydrogen bond
182
interactions (2.05 Å, 126.51°; 2.04 Å, 126.41°) with two 7g molecules. The interaction
AC C
EP
169
6
ACCEPTED MANUSCRIPT 183
between Cl atom present in 7g and H2O (2.844 Å, 139.05°) also exits. All the hydrogen
184
bonding interactions and the orientation of the molecules in the crystal lattice are shown in
185
Figure 2b and 2c along the c- and a-axis respectively. The single helix arrangement can also
186
be visualised from the a-axis is shown in Figure 2c.
187
The single crystal structure of 8l reveals that the three thiazole ring and the pyridyl
RI PT
188
ring systems attached to 2nd and 4th positions are aligned in same plane. Hence, the molecule
190
is planar as shown in the single crystal structure in ORTEP diagram with 40% ellipsoid
191
probability (Figure 3a). The crystal packing reveals that the two molecules of 8l are
192
stabilised by the two intermolecular hydrogen bonds (2.101 Å, 167.91°) between the NH
193
group present in the 2nd position of the thiazole ring and the N present in the 3-pydidyl ring
194
and vice versa. The crystal packing of the molecules with two intermolecular hydrogen bonds
195
along a- and b-axis is shown in Figure 3 b and c respectively. The alignment of 8l molecules
196
in the layered and single helical fashion can be viewed along the a-axis as shown in Figure
197
3b.
M AN U
SC
189
198 199
2.4. Antimycobacterial activity and structure activity relationship (SAR) studies
TE D
200
After successful completion of design, synthesis and structural confirmation, these
202
four classes of 2-aminothiazole derivatives have been evaluated for their antimycobacterial
203
activities by Resazurin microtiter assay (REMA), an in vitro assay against Mtb, H37Rv [40]. It
204
is interesting to note that anti-TB activity results are varied based on the substitutions at 2nd,
205
4th and 5th positions of thiazole ring. In the first category of compounds, firstly, 4-fluoro
206
phenyl attached in the 2nd positions of the 2-aminothiazole scaffold kept constant and the
207
substitutions at 4th position and 5th positions have been varied. The variations at 4th position
208
i.e., 4-chloro phenyl system (7a), exhibits good activity with MIC value 25 µM. When the
209
chlorine is replaced with bromine (7b), the potency increases to one fold with MIC value of
210
12.5 µM. Interestingly, when the H at 5th position of the 7b is replaced with the methyl group
211
(7c) and bromine (7d), the potentency drops down to the MIC values of 25 µM and 100 µM
212
respectively. This clearly indicates the importance of the 5th position and its scope in
213
identifying the successful candidates. Similarly, when the 4-bromo phenyl of 7b is replaced
214
with 4-methoxy phenyl (7f) and naphthalene, the potential is retained with 12.5 µM. To
215
understand the effect of phenyl derivatives attached on the 2nd positions of the 2-
216
aminothiazole scaffold, 4-hydroxy and 2-nitro- 4-chloro phenyl derivatives have been
AC C
EP
201
7
ACCEPTED MANUSCRIPT 217
prepared. When the fluorine present in the compounds 7a and 7f is replaced with 4-hydroxy
218
group, the compounds 7g and 7h loses their potentials and exhibit MIC values 100 µM and
219
200 µM respectively. Similarly, the compounds 7i and 7j, the 2-nitro- 4-chloro phenyl
220
replaced derivatives of 7f and 7e show no activity with MIC value of >200 µM and this result
221
shows the importance of fluorine at 4th position. In the second category of compounds, the substituted phenyl systems at 2nd position
RI PT
222
are same and phenyl systems at 4th position are replaced with pyridyl systems. Keeping the 3-
224
pyridyl system intact at 4th position and varying the 2nd position with 4-flouro (7k), 4-bromo
225
(7m), 4-hydroxy (7o) and 2-nitro- 4-chloro (7r) phenyl systems lead to formation of the
226
compounds with no antimycobacterial activity (>200 µM). Interestingly, when 3-pyridyl
227
system is replaced with 4-pyridyl system, the activity enhances in the case of 4-flouro (7l)
228
and 4-bromo (7n) with MIC values 25 µM and 6.25 µM respectively. But, the compounds
229
with 4-hydroxy (7p) and 2-nitro- 4-chloro (7s) phenyl systems show no activity. The 2-
230
pyridyl systems with 2-nitro- 4-chloro phenyl (7q) do not make any difference in the activity.
M AN U
231
SC
223
In the third class of compounds, the 2-pyridyl group is introduced at the 2nd position of the 2-aminothiazole. In addition to this, substituted phenyl systems at 4th position and
233
methyl or bromine at 5th position have also been introduced to investigate the effect of 2-
234
pyridyl system. Unfortunately, all these compounds have exhibited no inhibition with MIC
235
value >200 µM against the Mtb, H37Rv. Similarly, to understand the effect pyridine systems
236
on both sides of 2-aminothiazole scaffold, fourth category of compounds have been
237
synthesized by keeping 3- or 4-pyridyl system at 4th position and 2-pyridyl derivative of NH
238
at 2nd position. In this category, 8m and 8n inhibit Mtb with MIC value 100 µM and rest of
239
the compounds are inactive with MIC value >200 µM.
EP
Overall, 4-flourophenyl system at 2nd position and H at 5th position of 2-aminothiazole
AC C
240
TE D
232
241
are enhancing the activity in the first class of compounds. Similarly, in the second class of
242
compounds, 4-flouro and 4-bromophenyl system on the 2nd position and 4-pyridyl systems on
243
the 4th position are enhancing the activity. The structural changes in the third and fourth class
244
of compounds did not influence much on enhancing the antimycobacterial activity. The
245
structure activity relationship studies are summarised in the Figure 4. The effect of Log P on
246
inhibition of Mtb also analysed for all the 34 compounds and the results are summarised in
247
Figure 5. When the Log P value is increased from 3.08 to 3.46 (8n, 8f) there is no difference
248
in antimycobacterial activity, but, when it increases to 3.71 (7l) the activity also increased.
249
When the log P value is further increased to 4.33 (7g) the antimycobacterial activity
250
decreased significantly. Further increase of Log P value up to 4.77 (7m, 7f) increases the 8
ACCEPTED MANUSCRIPT 251
activity enormously. After this, the activity reduced when log P value reaches 5.09 (7e).
252
From 5.54 to 6.35 (7d, 7a, 7i and 7b) the antimycobacterial activity is very good. Further
253
increase from 6.35 to 6.64 (7c) decreases the activity. Overall, the antimycobacterial activity
254
of 2-aminothiazole was found to be good when the Log P value is from 4.25 to 4.75 and from
255
5.5 to 6.5.
257
RI PT
256
2.5. Docking studies with KasA protein
258 259
The positive in vitro results encouraged us to study their possible mode of action through in silico methods using docking studies. As 2-aminothiazole derivatives are
261
structurally similar to TLM and TLM is potential inhibitor of the KasA protein of Mtb, in the
262
present study, KasA protein has been chosen as receptor target. KasA protein plays a vital
263
role in the biosynthesis of mycolic acid, long chain fatty acids and the essential components
264
of the Mtb cell wall [24]. Hence among all the 2-aminothiazole derivatives, the compounds,
265
7b, 7n, 8a and 8n have been chosen as the representative compounds based on their in vitro
266
activities and structural variations.
M AN U
267
SC
260
As anticipated, the selected compounds have exhibited good interactions and inhibition constant (Ki) against KasA protein. The compounds, 7b, 7n, 8a and 8n have shown
269
the Ki values of 1.28 µM, 0.44 µM, 30.20 µM and 30.19 µM with a binding energy of -8.04
270
Kcal/mol, -8.66 Kcal/mol, -11.66 Kcal/mol and -11.81 Kcal/mol respectively. The inhibition
271
of the protein by 7n is attained through hydrogen bonding interactions of N present in the 4-
272
pyridyl ring present at the 4th position of the 2-aminothiazole ring with COOH of the
273
phenylalanine (PHE) – 402. In addition to this, the NH present at the 2nd position of the 2-
274
aminothiazole ring has shown the hydrogen bond interactions with threonine (THR) – 315
275
and THR – 313 residues as shown in Figure 6. Hence, from the correlation of the results
276
obtained by in vitro and in silico analyses, it may be concluded that the present molecules
277
could be targeting the KasA protein and in turn disturbing the cell wall biosynthesis by
278
obstructing mycolic acid synthesis.
AC C
EP
TE D
268
279 280
3. Conclusion
281 282
The designed 2-aminothiazole derivatives with variations in the Log P values have
283
been designed and synthesized. All the synthesized compounds have been evaluated for their
284
inhibitory potentials against Mtb, H37Rv and their SAR studies have been carried out. Among 9
ACCEPTED MANUSCRIPT all the compounds, 4-flourophenyl group at 2nd position of the 2-aminothiazole ring system
286
has been proven to be responsible for contributing the activity. The compound 7n has shown
287
the highest inhibition with the MIC values of 6.25 µM and 0.44 µM by in vitro and in silico
288
analyses respectively. The continuation of the efforts in identifying the new molecules with
289
special focus on the present lead compounds to achieve improved antimycobacterial activities
290
are under progress in our laboratory.
291
4.
292
4.1. Materials and methods
Experimental
The substituted anilines, 2-, 3- or 4- acetyl pyridines, benzoyl chloride and aryl α –
SC
293
RI PT
285
haloketones were purchased either from Sigma–Aldrich, USA or Himedia Biosciences or
295
Spectrochem Pvt. Ltd (Mumbai, India). The chemicals procured were used without further
296
purification. The spectral data obtained by 1H NMR and 13C NMR were recorded with 400
297
MHz and 101 MHz Bruker Avance-II NMR instrument. Thermo Nicolet 6700 FT-IR
298
spectrometer was used to record the IR spectra and only major peaks are reported in cm-1.
299
Similarly, Elementar Vario EL-II CHNS analyzer was used for the Elemental analysis of all
300
the compounds. Chemical ionization (CI) or negative-ion electrospray ionization (ESI)
301
method was used to record the mass spectra (MS) by Thermo Scientific High Resolution
302
Magnetic Sector MS DFS. For the analysis of single crystals, Oxford diffractometer was used
303
and CrysAlis PRO, Oxford Diffraction Ltd., Version 1.171.34.44 (release 25-10-2010
304
CrysAlis171. NET) software has been used for the data collection, cell refinement and data
305
reduction purposes. The olex2.solve (compiled Oct 25 2010, 18:11:34) and SHELXL have
306
been used for solving the structure and to refine single crystal respectively. ChemBioDraw
307
Ultra has been used to deduce all the IUPAC names for the synthesized compounds.
TE D
EP
AC C
308
M AN U
294
309 310 311
4.2. General procedure for the synthesis of phenylthioureas (1a-d)
312
anilines (0.1 mol) were added and warmed to get a clear solution. Ammonium thiocyanate
313
(0.11 mol) dissolved in water (15 mL) was gradually added to this solution. The reaction
314
mixture was refluxed till the completion of the reaction and then more than the half of the
315
volume of the water present in the reaction mixture was distilled off. The phenyl thiourea was
To the dilute hydrochloric acid (15 mL) solution, the corresponding substituted
10
ACCEPTED MANUSCRIPT 316
obtained on gradual cooling of the reaction mixture, and it was filtered, washed with water
317
and recrystallized from ethanol.
318 319 320 321
4.3. General procedure for the synthesis of pyridylthioureas (3a-c)
322
chloride (65 mmol) was added dropwise by maintaining temperature between 20 – 25 °C.
323
Then the temperature of reaction mixture was raised to reflux temperature and stirred for 15
324
to 30 min. Then, the reaction mixture was cooled to 25 °C and appropriate pyridyl amine (64
325
mmol) was added gradually. The mixture was stirred at reflux temperature for a further 30
326
min, cooled to 20 °C, and poured on to ice. The mixture was stirred for another 30 min., and
327
then the precipitate was filtered, washed with water (15 mL) and dried. The solid was added
328
to a solution of NaOH (10% w/v, 100 mL) at 80 °C and continued stirring for 30 min, then
329
cooled to 20 °C and poured onto ice/HCl (6 M, 50 mL) solution. The pH of the mixture was
330
adjusted to 10 using conc. NH3 solution and stirred for 30 min. The precipitate was filtered
331
and washed with water (20 mL) and dried. The precipitate was purified by recrystallization
332
from ethanolic solution to afford the desired product in 85-95% yield.
M AN U
SC
RI PT
In dry acetone (50 mL), NH4SCN (69 mmol) was taken and to this solution, benzoyl
333
335 336
4.4. General procedure for the synthesis of (bromoacetyl)pyridines (5a-c)
TE D
334
Corresponding acetylpyridine (80 mmol) was taken in 30 % HBr/AcOH (100 mL) and to this stirred solution, Br2 (80 mmol) was added dropwise at 15 °C. The mixture was stirred
338
at 40 °C for 1 h and then at 75 °C for 1 h. Then, the reaction mixture was cooled to 20 °C.
339
The cooled reaction mixture was diluted with Et2O (400 mL), and continued to stir for 30
340
min. The precipitate obtained was filtered, washed with Et2O (25 mL), and dried under
341
vacuum to give the (bromoacetyl)pyridines as the hydrobromide salt [51].
AC C
342
EP
337
343 344 345
4.5. General procedure for the synthesis of titled 2-aminothiazole analogues (7a-8o)
346
solution, corresponding α-bromoacetylpyridine (1 mmol) or α-haloacetophenone (1 mmol)
347
derivative was added at 25- 30 °C. The reaction mixture was refluxed for 3-5 h or until the
348
reaction was complete as evidenced using TLC. Then, the reaction mixture was gradually
349
poured into ice-water (20 mL) and stirred for another 30 min. To this, aqueous 1N Na2CO3
350
solution was added to neutralise and to maintain pH ∼ 8. The precipitated aminothiazole
The appropriate thiourea (1 mmol) was dissolved in ethanol (∼10 mL) and to this
11
ACCEPTED MANUSCRIPT 351
derivatives were filtered and collected. The crude 2-aminothiazoles were purified by
352
recrystallization from ethanol.
353 354
4.5.1. 4-(4-Chlorophenyl)-N-(4-fluorophenyl)thiazol-2-amine (7a) White solid from EtOH (88% yield). m.p. 170.3-171.5 °C; 1H NMR (400 MHz,
356
CDCl3): δ 7.75 – 7.73 (m, 1H), 7.48 – 7.36 (m, 2H), 7.13 (dd, J = 9.1, 8.1 Hz, 1H), 6.70 (s,
357
1H), 3.40 (s, 1H);
358
132.46, 129.58, 127.58, 123.68, 122.73, 122.64, 117.06, 117.06, 116.83, 116.83, 104.05; IR
359
(KBr): 3255, 3066, 1607, 1505, 1404, 1238, 1091, 841, 769 cm-1. Anal. Calcd. for
360
C15H10ClFN2S: C, 59.11; H, 3.31; N, 9.19; S, 10.52; found: C, 59.13; H, 3.37; N, 9.22; S,
361
10.53; HR-MS (ESI+): m/z [M + H]
362
02330.
C NMR (101 MHz, DMSO-d6): δ 167.43, 159.22, 145.12, 134.49,
364
Calcd. for C15H10ClFN2S: 304.02326; found: 304.
M AN U
363
+
SC
13
RI PT
355
4.5.2. 4-(4-Bromophenyl)-N-(4-fluorophenyl)thiazol-2-amine (7b) White solid from EtOH (86% yield). m.p. 179.5 – 180.5 °C; 1H NMR (400 MHz,
366
CDCl3): δ 7.67 (d, J = 8.7 Hz, 1H), 7.56 (d, J = 8.7 Hz, 1H), 7.40 (dd, J = 9.1, 4.5 Hz, 1H),
367
7.12 (dd, J = 9.1, 8.1 Hz, 1H), 6.72 (s, 1H). 13C NMR (101 MHz, CDCl3): δ 167.43, 159.22,
368
145.12, 134.49, 132.46, 129.58, 127.58, 123.68, 122.73, 122.64, 117.06, 116.83, 100.55; IR
369
(KBr): 3254, 3065, 1606, 1504, 1401, 1238, 1006, 840, 729 cm-1. Anal. Calcd. for
370
C15H10BrFN2S: C, 51.59; H, 2.89; N, 8.02; S, 9.18; found: C, 51.57; H, 2.92; N, 8.04; S, 9.21;
371
HR-MS (ESI+): m/z [M + H] + Calcd. for C15H10BrFN2S: 347.97320; found: 347.97322.
TE D
365
373
4.5.3
EP
372
4-(4-Bromophenyl)-N-(4-fluorophenyl)-5-methylthiazol-2-amine (7c) White solid from EtOH (88% yield). m.p. 252.6-254°C; 1H NMR (400 MHz, DMSO-
375
d6): δ 7.67 (d, J = 8.7 Hz, 1H), 7.56 (d, J = 8.7 Hz, 1H), 7.40 (dd, J = 9.1, 4.5 Hz, 1H), 7.12
376
(dd, J = 9.1, 8.1 Hz, 1H), 6.72 (s, 1H), 2.45(s, 3H);
377
160.96, 158.81, 156.40, 141.84, 137.03, 132.91, 131.42, 130.25, 120.83, 119.88, 117.12,
378
115.65, 11.94; IR (KBr): 3448, 3074, 1621, 1594, 1506, 1230, 1002, 826, 645 cm-1. Anal.
379
Calcd. for C16H12BrFN2S: C, 52.90; H, 3.33; N, 7.71; S, 8.83; found: C, 52.92; H, 3.34; N,
380
7.70; S, 8.81; HR-MS (ESI+): m/z [M + H]
381
361.98890.
AC C
374
+
13
C NMR (101 MHz, DMSO-d6): δ
Calcd. for C16H12BrFN2S: 361.98886; found:
382 383
4.5.4. 5-Bromo-4-(4-bromophenyl)-N-(4-fluorophenyl)thiazol-2-amine (7d)
12
ACCEPTED MANUSCRIPT 384
White solid from EtOH (92% yield). m.p. 258.7-259.5°C; 1H NMR (400 MHz,
385
DMSO-d6): δ 10.32 (s, 1H), 8.88 (d, J = 8.7 Hz, 2H), 8.42 (d, J = 8.7 Hz, 2H), 7.53 (d, J =
386
8.1Hz, 2H), 6.80 (d, J = 8.1 Hz, 2H);
387
152.22, 138.30, 136.91, 134.14, 128.84, 123.01, 118.54, 116.33, 94.05; IR (KBr): 3438,
388
3068, 1625, 1598, 1511, 1236, 1001, 828, 644 cm-1. Anal. Calcd. for C15H9Br2FN2S: C,
389
42.08; H, 2.12; N, 6.54; S, 7.49; found: C, 42.10; H, 2.13; N, 6.57; S, 7.43; HR-MS (ESI+):
390
m/z [M + H] + Calcd. for C15H9Br2FN2S: 427.88168; found: 427.88168.
C NMR (101 MHz, DMSO-d6): δ 165.58, 158.06,
RI PT
13
391 392
4.5.5. N-(4-Fluorophenyl)-4-(naphthalen-2-yl)thiazol-2-amine (7e)
White solid from EtOH (91% yield). m.p. 171.5-175.3 °C; 1H NMR (400 MHz,
394
CDCl3): δ 8.35 (d, J = 1.3 Hz, 1H), 7.96 (dd, J = 6.1, 3.4 Hz, 1H), 7.89 (d, J = 8.6 Hz, 1H),
395
7.82 (dd, J = 6.0, 3.4 Hz, 1H), 7.75 (dd, J = 8.6, 1.9 Hz, 1H), 7.55 – 7.50 (m, 2H), 7.38 (dd, J
396
= 9.0, 4.5 Hz, 2H), 7.15 (dd, J = 8.9, 8.1 Hz, 2H), 6.78 (s, 1H), 5.27 (s, 1H); 13C NMR (101
397
MHz, CDCl3): δ 168.41, 133.84, 133.29, 129.48, 129.04, 127.75, 125.99 123.59, 122.66,
398
117.38, 117.15, 99.32; IR (KBr): 3251, 3049, 1625, 1503, 1231, 1158, 818, 750 cm-1. Anal.
399
Calcd. for C19H13FN2S: C, 71.23; H, 4.09; N, 8.74; S, 10.01; found: C, 71.24; H, 4.11; N,
400
8.75; S, 10.03. HR-MS (ESI+): m/z [M + H]
401
320.07839.
+
Calcd. for C19H13FN2S: 320.07835; found:
TE D
402 403
M AN U
SC
393
4.5.6. N-(4-Fluorophenyl)-4-(4-methoxyphenyl)thiazol-2-amine (7f) White solid from EtOH (87% yield). m.p. 231.5-234.3 °C; 1H NMR (400 MHz,
405
CDCl3): δ 11.54 (s, 1H), 7.72 (d, J = 8.9 Hz, 2H), 7.44 – 7.34 (m, 2H), 7.18 (dd, J = 9.1, 8.0
406
Hz, 2H), 7.01 (d, J = 8.9 Hz, 2H), 6.49 (s, 1H), 3.85 (s, 3H); 13C NMR (101 MHz, CDCl3): δ
407
164.08, 144.85, 142.28, 136.60, 129.41, 122.08, 121.99, 121.62, 120.49, 116.64, 116.41,
408
113.23, 17.46, 14.55; IR (KBr): 3212, 3015, 1619, 1505, 1292, 1255, 1022, 883 cm-1. Anal.
409
Calcd. for C16H13FN2OS: C, 63.98; H, 4.36; N, 9.39; S, 10.68; found: C, 63.99; H, 4.39; N,
410
9.37; S, 10.71. HR-MS (ESI+): m/z [M + H] + Calcd. for C16H13FN2OS: 300.07326; found:
411
300.07331.
AC C
EP
404
412 413
4.5.7. 4-(4-(4-Chlorophenyl)thiazol-2-ylamino)phenol (7g)
414
White solid from EtOH (87% yield). m.p. 196.3-198.3 °C; 1H NMR (400 MHz,
415
DMSO-d6): δ 9.93 (s, 1H), 9.15 (s, 1H), 7.90 (d, J = 8.7 Hz, 1H), 7.47 (d, J = 1.2 Hz, 1H),
416
7.45 (d, J = 1.4 Hz, 1H), 6.75 (d, J = 8.9 Hz, 1H); 13C NMR (101 MHz, DMSO-d6): δ 164.43,
417
152.42, 148.83, 133.54, 133.22, 131.85, 128.64, 127.36, 119.35, 115.52, 102.70; IR (KBr): 13
ACCEPTED MANUSCRIPT 418
3562, 3293, 3067, 1573, 1511, 1224, 672 cm-1. Anal. Calcd. for C15H11ClN2OS: C, 59.50; H,
419
3.66; N, 9.25; S, 10.59; found: C, 59.52; H, 3.68; N, 9.28; S, 10.62. HR-MS (ESI+): m/z [M
420
+ H] + Calcd. for C15H11ClN2OS: 302.02806; found: 302.02809.
421 422
4.5.8. 4-((4-(4-Methoxyphenyl)thiazol-2-yl)amino)phenol (7h) White solid from EtOH (88% yield). m.p. 126.3-128.3 °C; 1H NMR (400 MHz,
424
DMSO-d6): δ 9.93 (s, 1H), 9.15 (s, 1H), 7.90 (d, J = 8.7 Hz, 1H), 7.47 (d, J = 1.2 Hz, 1H),
425
7.45 (d, J = 1.4 Hz, 1H), 6.75 (d, J = 8.9 Hz, 1H), 3.85 (s, 3H );
426
DMSO-d6): δ 161.13, 151.39, 147.49, 132.45, 128.01, 125.22, 121.34, 117.15, 111.85,
427
104.90, 55.63; IR (KBr): 3562, 3293, 3067, 1573, 1511, 1224, 672 cm-1. Anal. Calcd. for
428
C15H11ClN2OS: C, 59.50; H, 3.66; N, 9.25; S, 10.59; found: C, 59.52; H, 3.68; N, 9.28; S,
429
10.62. HR-MS (ESI+): m/z [M + H]
430
302.02809.
RI PT
423
SC
C NMR (101 MHz,
Calcd. for C15H11ClN2OS: 302.02806; found:
M AN U
431 432
+
13
4.5.9. N-(4-Chloro-2-nitrophenyl)-4-(4-methoxyphenyl)thiazol-2-amine (7i) Yellow solid from EtOH (89% yield). m.p. 150.2-151.5 °C; 1H NMR (400 MHz,
434
DMSO-d6): δ 10.39 (s, 1H), 9.02 (d, J = 9.3 Hz, 1H), 8.37 (d, J = 2.6 Hz, 1H), 8.33 (dd, J =
435
9.3, 2.6 Hz, 1H), 7.93 (d, J = 8.7 Hz, 1H), 7.49 (s, 1H), 7.04 (d, J = 8.8 Hz, 1H), 3.85 (s, 1H);
436
13
437
124.15, 119.91, 117.73, 114.07, 105.16, 55.17; IR (KBr): 3390, 3102, 1590, 1503, 1335,
438
1280, 1176, 835, 739 cm-1. Anal. Calcd. for C16H12ClN3O3S: C, 53.11; H, 3.34; N, 11.61; S,
439
8.86; found: C, 53.14; H, 3.36; N, 11.68; S, 8.89. HR-MS (ESI+): m/z [M + H] + Calcd. for
440
C16H12ClN3O3S: 361.02879; found: 361.02883.
442 443
EP
C NMR (101 MHz, DMSO-d6): δ 161.41, 159.03, 149.71, 143.41, 140.19, 127.17, 125.09,
AC C
441
TE D
433
4.5.10. N-(4-Chloro-2-nitrophenyl)-4-(naphthalen-2-yl)thiazol-2-amine (7j) Yellow solid from EtOH (92% yield). m.p. 223.2-224.4 °C; 1H NMR (400 MHz,
444
DMSO-d6): δ 10.40 (s, 1H), 9.08 (d, J = 9.3 Hz, 1H), 8.48 (s, 1H), 8.34 (dd, J = 9.3, 2.4 Hz,
445
1H), 8.30 (d, J = 2.4 Hz, 1H), 8.07 (d, J = 8.6 Hz, 1H), 8.03 (d, J = 7.7 Hz, 1H), 7.95 (d, J =
446
8.6 Hz, 1H), 7.91 (d, J = 7.7 Hz, 1H), 7.73 (s, 1H), 7.56 – 7.46 (m, 1H); 13C NMR (101 MHz,
447
DMSO-d6): δ 161.58, 149.71, 143.28, 140.19, 133.14, 132.50, 128.25, 128.15, 127.51,
448
126.35, 126.05, 124.97, 124.41, 124.19, 123.90, 107. 86; IR (KBr): 3377, 3108, 1589, 1544,
449
1496, 1324, 1281, 1121, 892, 746 cm-1. Anal. Calcd. for C19H12ClN3O2S: C, 59.76; H, 3.17;
450
N, 11.00; S, 8.40; found: C, 59.79; H, 3.19; N, 11.04; S, 8.43. HR-MS (ESI+): m/z [M + H] +
451
Calcd. for C19H12ClN3O2S: 381.03388; found: 381.03393. 14
ACCEPTED MANUSCRIPT 452 453
4.5.11. N-(4-Fluorophenyl)-4-(pyridin-3-yl)thiazol-2-amine (7k)
454
Antique white solid from EtOH (91% yield). m.p. 181.5-188.1 °C; 1H NMR (400
455
MHz, CDCl3 + DMSO-d6): δ 10.19 (s, 1H), 9.60 (s, 1H), 9.10 (d, J = 1.6 Hz, 1H), 8.46 (dd, J
456
= 4.7, 1.3 Hz, 1H), 8.30 – 8.09 (m, 1H), 7.72 (dd, J = 9.1, 4.8 Hz, 2H), 7.36 (dd, J = 7.9, 4.8
457
Hz, 1H), 7.05 (t, J = 8.8 Hz, 2H);
458
147.85, 147.07, 137.35, 132.67, 130.08, 123.28, 118.26, 115.15, 114.93, 103.69; IR (KBr):
459
3443, 3114, 1619, 1576, 1508, 1402, 1225, 1021, 819, 710 cm-1. Anal. Calcd. for
460
C14H10FN3S: C, 61.98; H, 3.72; N, 15.49; S, 11.82; found: C, 61.99; H, 3.75; N, 15.54; S,
461
11.85. HR-MS (ESI+): m/z [M + H] + Calcd. for C14H10FN3S: 271.05795; found: 271.05797.
C NMR (101 MHz, CDCl3 + DMSO-d6): δ 163.58,
SC
RI PT
13
462 463
4.5.12. N-(4-Fluorophenyl)-4-(pyridin-4-yl)thiazol-2-amine (7l)
Yellow solid from EtOH (88% yield). m.p. 283.5-284.3 °C; 1H NMR (400 MHz,
465
DMSO-d6): δ 10.72 (s, 1H), 8.91 (d, J = 6.7 Hz, 2H), 8.45 (d, J = 6.7 Hz, 2H), 8.33 (s, 1H),
466
7.79 (dd, J = 8.9, 4.8 Hz, 2H), 7.18 (t, J = 8.8 Hz, 2H); 13C NMR (101 MHz, DMSO-d6): δ
467
163.93, 156.00, 148.73, 145.25, 142.12, 137.13, 122.31, 118.82, 115.72, 115.50; IR (KBr):
468
3238, 3204, 3048, 1630, 1545, 1501, 1410, 1214, 826, 770 cm-1. Anal. Calcd. for
469
C14H10FN3S, C, 61.98; H, 3.72; N, 15.49; S, 11.82; found: C, 61.99; H, 3.75; N, 15.53; S,
470
11.85. HR-MS (ESI+): m/z [M + H] + Calcd. for C14H10FN3S: 271.05795; found: 271.05798.
471
4.5.13. N-(4-Bromophenyl)-4-(pyridin-3-yl)thiazol-2-amine (7m)
TE D
M AN U
464
Yellow solid from EtOH (91% yield). m.p. 256.2-256.4 °C; 1H NMR (400 MHz,
473
DMSO-d6): δ 10.67 (s, 1H), 9.36 (d, J = 7.2 Hz, 1H), 9.06 – 8.88 (m, 1H), 8.86 – 8.74 (m,
474
1H), 8.06 (s, 1H), 7.91 (d, J = 10.4 Hz, 1H), 7.82 – 7.75 (m, 1H), 7.39 (d, J = 8.8 Hz, 1H);
475
13
476
109.09. IR (KBr): 3227, 3174, 3059, 1600, 1559, 1486, 1246, 820, 678 cm-1. Anal. Calcd. for
477
C14H10BrN3S: C, 50.61; H, 3.03; N, 12.65; S, 9.65; found: C, 50.64; H, 3.04; N, 12.68; S,
478
9.64. HR-MS (ESI+): m/z [M + H] + Calcd. for C14H10BrN3S, 330.97788; found: 330.97792.
AC C
EP
472
C NMR (101 MHz, DMSO-d6): δ 163.62, 140.86, 139.63, 132.82, 128.77, 126.97, 118.60,
479 480
4.5.14. N-(4-Bromophenyl)-4-(pyridin-4-yl)thiazol-2-amine (7n)
481
Yellow solid from EtOH (94% yield). m.p. 281-282.5 °C; 1H NMR (400 MHz,
482
DMSO-d6): δ 10.82 (s, 1H), 8.92 (d, J = 6.8 Hz, 2H), 8.47 (d, J = 6.9 Hz, 2H), 8.37 (s, 1H),
483
7.80 (d, J = 9.0 Hz, 2H), 7.39 (d, J = 8.7 Hz, 2H); 13C NMR (101 MHz, DMSO-d6): δ 163.57,
15
ACCEPTED MANUSCRIPT 484
142.23, 128.88, 122.30, 118.71, 116.08; IR (KBr): 3221, 3173, 3043, 2717, 1631, 1544,
485
1488, 1310, 820, 667 cm-1. Anal. Calcd. for C14H10BrN3S: C, 50.61; H, 3.03; N, 12.65; S,
486
9.65; found: C, 50.62; H, 3.06; N, 12.68; S, 9.67. HR-MS (ESI+): m/z [M + H] + Calcd. for
487
C14H10BrN3S: 330.97788; found: 330.97793.
488
4.5.15. 4-(4-(Pyridin-3-yl)thiazol-2-ylamino)phenol (7o)
RI PT
489
Brown solid from EtOH (95% yield). m.p. 256.2-257.8 °C; 1H NMR (400 MHz,
491
CDCl3 + DMSO-d6): δ 9.66 (s, 1H), 9.05 (s, 1H), 8.84 (s, 1H), 8.43 (s, 1H), 8.13 (d, J = 7.7
492
Hz, 1H), 7.41 (d, J = 8.0 Hz, 2H), 7.33 (d, J = 4.3 Hz, 1H), 6.99 (s, 1H), 6.71 (d, J = 8.0 Hz,
493
2H); 13C NMR (101 MHz, CDCl3 + DMSO-d6): δ 164.92, 152.27, 147.39, 147.04, 146.52,
494
132.87, 119.29, 115.21, 102.35; IR (KBr): 3229, 3125, 1606, 1568, 1410, 1241, 831, 722 cm-
495
1
496
4.14; N, 15.63; S, 11.94. HR-MS (ESI+): m/z [M + H] + Calcd. for C14H11N3OS: 269.06228;
497
found: 269.06231.
SC
490
M AN U
. Anal. Calcd. for C14H11N3OS: C, 62.43; H, 4.12; N, 15.60; S, 11.91; found: C, 62.45; H,
498 499
4.5.16. 4-(4-(Pyridin-4-yl)thiazol-2-ylamino)phenol (7p)
Dark red solid from EtOH (91% yield). m.p. 267.2-268.0 °C; 1H NMR (400 MHz,
501
DMSO-d6): δ 10.32 (s, 3H), 9.07 (m, 2H), 8.87 (d, J = 6.7 Hz, 6H), 8.41 (d, J = 6.8 Hz, 6H),
502
8.22 (s, 3H), 7.52 (d, J = 8.8 Hz, 6H), 6.79 (d, J = 8.8 Hz, 6H); 13C NMR (101 MHz, DMSO-
503
d6): δ 164.85, 152.80, 148.96, 145.36, 142.00, 132.71, 122.30, 119.61, 115.63, 115.02; IR
504
(KBr): 3468, 3215, 3025, 1636, 1561, 1433, 1259, 828, 747 cm-1. Anal. Calcd. for
505
C14H11N3OS, C, 62.43; H, 4.12; N, 15.60; S, 11.91; found: C, 62.45; H, 4.16; N, 15.63; S,
506
11.94. HR-MS (ESI+): m/z [M + H] + Calcd. for C14H11N3OS: 269.06228; found: 269.0623.
EP
TE D
500
508 509
AC C
507
4.5.17. N-(4-Chloro-2-nitrophenyl)-4-(pyridin-2-yl)thiazol-2-amine (7q) Yellow solid from EtOH (92% yield). m.p. 311.6-312.5 °C; 1H NMR (400 MHz,
510
DMSO-d6): δ 11.91 (s, 1H), 8.60 (d, J = 7.8, 1H), 8.22 (d, J = 7.8, 1H), 8.05 (d, J = 7.8, 1H),
511
7.86 (t, J = 7.3, 1H), 7. 63 (d, J = 7.8, 1H), 7.42 – 7.37 (t, J = 7.3, 1H), 7.19 (s, 1H), 6.83 (d, J
512
= 7.7, 1H);
513
137.47, 135.24, 132.45, 127.45, 122.72, 121.60, 117.99, 105.18; IR (KBr): 3205, 3085, 1597,
514
1544, 1494, 1335, 1275, 756 cm-1. Anal. Calcd. for C14H9ClN4O2S: C, 50.53; H, 2.73; N,
515
16.84; S, 9.64; found: C, 50.55; H, 2.74; N, 16.86; S, 9.65. HR-MS (ESI+): m/z [M + H]
516
Calcd. for C14H9ClN4O2S: 332.01347; found: 332.01349.
13
C NMR (101 MHz, DMSO-d6): δ 161.41, 154.44, 149.98, 143.31, 141.64,
517 16
+
ACCEPTED MANUSCRIPT 518
4.5.18. N-(4-Chloro-2-nitrophenyl)-4-(pyridin-3-yl)thiazol-2-amine (7r)
519
Yellow solid from EtOH (88% yield). m.p.342.3-343.7 °C; 1H NMR (400 MHz,
520
DMSO-d6): δ 10.52 (s, 1H), 9.42 (s, 1H), 9.01 (d, J = 8.1 Hz, 1H), 8.96 (d, J = 9.3 Hz, 1H),
521
8.85 (d, J = 5.1 Hz, 1H), 8.28 (d, J = 2.2 Hz, 1H), 8.22 (dd, J = 9.3, 2.3 Hz, 1H), 8.14 (s, 1H),
522
8.08 (dd, J = 7.9, 5.8 Hz, 1H);
523
140.88, 140.31, 139.57, 132.33, 126.82, 124.75, 123.80, 120.11, 118.22, 112.47; IR (KBr):
524
3212, 3060, 1589, 1549, 1498, 1326, 1282, 1121, 816, 678 cm-1. Anal. Calcd. for
525
C14H9ClN4O2S: C, 50.53; H, 2.73; N, 16.84; S, 9.64; found: C, 50.56; H, 2.72; N, 16.85; S,
526
9.67. HR-MS (ESI+): m/z [M + H]
527
332.01352.
13
Calcd. for C14H9ClN4O2S: 332.01347; found:
SC
+
RI PT
C NMR (101 MHz, DMSO-d6): δ 162.45, 143.42, 142.62,
528 529
4.5.19. N-(4-Chloro-2-nitrophenyl)-4-(pyridin-4-yl)thiazol-2-amine (7s)
Yellow solid from EtOH (89% yield). m.p. 332.8 – 333.4 °C; 1H NMR (400 MHz,
531
DMSO-d6): δ 10.64 (s, 4H), 8.98 (d, J = 9.3 Hz, 6H), 8.91 (d, J = 5.4 Hz, 6H), 8.52 (s, 6H),
532
8.49 (d, J = 5.5 Hz, 5H), 8.36 (s, 3H), 8.28 (d, J = 8.9 Hz, 2H); 13C NMR (101 MHz, DMSO-
533
d6): δ 162.82, 147.85, 144.93, 142.77, 140.82, 129.29, 125.12, 123.98, 122.26, 120.60,
534
118.56; IR (KBr): 3231, 3046, 1632, 1602, 1548, 1502, 1324, 1120, 825, 738 cm-1. Anal.
535
Calcd. for C14H9ClN4O2S: C, 50.53; H, 2.73; N, 16.84; S, 9.64; found: C, 50.54; H, 2.75; N,
536
16.86; S, 9.65. HR-MS (ESI+): m/z [M + H] + Calcd. for C14H9ClN4O2S: 332.01347; found:
537
332.01353.
TE D
M AN U
530
538
4.5.20. 4-(4-Methoxyphenyl)-N-(pyridin-2-yl)thiazol-2-amine (8a)
EP
539
Light yellow solid from EtOH (87% yield). m.p. 261.5-262.3 °C; 1H NMR (400 MHz,
541
DMSO-d6): δ 11.91 (s, 1H), 8.60 (d, J = 7.8 Hz, 1H), 8.05 (d, J = 7.8 Hz, 1H), 7.86 (t, J = 7.8
542
Hz, 1H), 7.65 (s, 1H) 7.52 (d, J = 8.2 Hz, 2H), 7.40 (t, J = 7.8 Hz, 1H), 7.07 (d, J = 8.2 Hz,
543
2H), 2.98 (s, 3H);
544
138.30, 128.01, 124.39, 117.42, 114.36, 108.25, 103.23, 55.92; IR (KBr): 3231, 3077, 1618,
545
1559, 1474, 1429, 1344, 1238, 771, 671 cm-1. Anal. Calcd. for C15H13N3OS: C, 63.58; H,
546
4.62; N, 14.83; S, 11.32; found: C, 63.55; H, 4.65; N, 14.86; S, 11.36. HR-MS (ESI+): m/z
547
[M + H] + Calcd. for C15H13N3OS: 283.07793; found: 283.07795.
AC C
540
13
C NMR (101 MHz, DMSO-d6): δ 162.24, 154.73, 150.56, 147.77,
548 549
4.5.21. 4-(4-Bromophenyl)-N-(pyridin-2-yl)thiazol-2-amine (8b)
550
Light yellow solid from EtOH (92% yield). m.p. 281.5-282.1 °C; 1H NMR (400 MHz,
551
DMSO-d6): δ 12.49 (s, 1H), 8.44 (s, 1H), 7.96 (d, J = 3.8 Hz, 1H), 7.80 (d, J = 7.8 Hz, 2H), 17
ACCEPTED MANUSCRIPT 13
7.51 (d, J = 6.6 Hz, 2H), 7.42 (s, 1H), 7.36 (s, 1H), 7.14 (s, 1H);
553
DMSO-d6): δ 161.41, 155.84, 149.98, 148.04, 138.30, 132.73, 131.35, 128.01, 123.27,
554
117.99, 107.69, 104.61, 40.15, 39.94, 39.74, 39.53, 39.32, 39.11, 38.90; IR (KBr): 3231,
555
3077, 1618, 1559, 1474, 1429, 1344, 1238, 771, 671 cm-1. Anal. Calcd. for C14H10BrN3S: C,
556
50.61; H, 3.03; N, 12.65; S, 9.65; found: C, 50.64; H, 3.05; N, 12.67; S, 9.68 HR-MS (ESI+):
557
m/z [M + H] + Calcd. for C14H10BrN3S: 330.97788; found: 330.97788.
558 559
C NMR (101 MHz,
RI PT
552
4.5.22. 4-(4-Bromophenyl)-5-methyl-N-(pyridin-2-yl)thiazol-2-amine (8c)
White solid from EtOH (90% yield). m.p. 277.5-278.2 °C; 1H NMR (400 MHz,
561
DMSO-d6): δ 11.85 (s, 1H), 8.35 (dd, J = 5.4, 1.0 Hz, 1H), 7.90 – 7.85 (m, 1H), 7.64 (d, J =
562
2.9 Hz, 2H), 7.21 (d, J = 8.5 Hz, 1H), 7.09 – 7.04 (m, 1H), 2.45 (s, 1H); 13C NMR (101 MHz,
563
DMSO-d6): δ 161.52, 156.39, 150.39, 144.03, 141.70, 133.22, 131.37, 130.22, 120.72,
564
120.46, 116.65, 112.07, 11.82; IR (KBr): 3231, 3077, 1618, 1559, 1474, 1429, 1344, 1238,
565
771, 671 cm-1. Anal. Calcd. for C15H12BrN3S: C, 52.03; H, 3.49; N, 12.14; S, 9.26; found: C,
566
52.06; H, 3.51; N, 12.17; S, 9.28. HR-MS (ESI+): m/z [M + H] + Calcd. for C15H12BrN3S:
567
344.99353; found: 344.99356.
568 569
M AN U
SC
560
4.5.23. 5-Bromo-4-(4-bromophenyl)-N-(pyridin-2-yl)thiazol-2-amine (8d) White solid from EtOH (86% yield). m.p. 230.1-232 °C; 1H NMR (400 MHz, DMSO-
571
d6): δ 11.89 (s, 1H), 8.38 (d, J = 4.8 Hz, 1H), 7.90 (d, J = 8.3 Hz, 2H), 7.62 (s, 1H), 7.60 (d, J
572
= 2.7 Hz, 1H), 7.23 (d, J = 8.4 Hz, 1H), 7.09 – 7.04 (m, 1H); 13C NMR (101 MHz, DMSO-
573
d6): δ 159.96, 150.63, 147.58, 144.18, 140.05, 133.38, 131.61, 127.88, 120.83, 116.54,
574
112.03, 107.50; IR (KBr): 3474, 3070, 1649, 1615, 1525, 1452, 1198, 832, 767, 668 cm-1.
575
Anal. Calcd. for C14H9Br2N3S: C, 40.90; H, 2.21; N, 10.22; S, 7.80; found: C, 40.93; H, 2.23;
576
N, 10.25; S, 7.84. HR-MS (ESI+): m/z [M + H] + Calcd. for C14H9Br2N3S: 408.88839; found:
577
408.88842.
579
EP
AC C
578
TE D
570
4.5.24. 4-(3,4-Dichlorophenyl)-N-(3-methylpyridin-2-yl)thiazol-2-amine (8e)
580
White solid from EtOH (88% yield). m.p. 276.2-278.1 °C; 1H NMR (400 MHz,
581
DMSO-d6): δ 11.21 (s, 1H), 8.06 (d, J = 8.9 Hz, 1H), 7.95 (s, 1H), 7.86 (d, J = 5.2 Hz, 1H),
582
7.62 (s, 1H), 7.49 (d, J = 7.5 Hz, 1H), 7.05 (t, J = 7.5 Hz, 1H), 6.91 (d, J = 7.8 Hz, 1H), 2.46
583
(s, 3H); 13C NMR (101 MHz, DMSO-d6): δ 163.08, 160.02, 151.66, 146.10, 138.30, 134.40,
584
131.90, 131.84, 129.39, 129.11, 125.78, 117.71, 113.52, 106.02; IR (KBr): 3421, 3083, 1637,
585
1583, 1489, 1258, 1191, 783, 738 cm-1. Anal. Calcd. for C15H11Cl2N3S: C, 53.58; H, 3.30; N, 18
ACCEPTED MANUSCRIPT 586
12.50; S, 9.54; found: C, 53.62; H, 3.32; N, 12.55; S, 9.56. HR-MS (ESI+): m/z [M + H]
587
Calcd. for C15H11Cl2N3S: 335.00507; found: 335.00509.
+
588 589
4.5.25. 4-(4-Bromophenyl)-5-methyl-N-(3-methylpyridin-2-yl)thiazol-2-amine (8f) Light Yellow solid from EtOH (94% yield). m.p. 243.1-244.5 °C; 1H NMR (400
591
MHz, DMSO-d6): δ 11.73 (s, 1H), 7.77 (t, J = 7.3 Hz, 1H), 7.69 (dd, J = 16.6, 8.5 Hz, 1H),
592
7.02 (d, J = 8.1 Hz, 1H), 6.95 (d, J = 7.2 Hz, 1H), 2.55 (s, 1H); 13C NMR (101 MHz, DMSO-
593
d6): δ 162.80, 157.78, 147.77, 145.25, 136.64, 133.29, 131.62, 128.56, 123.82, 117.42,
594
115.76, 113.52; IR (KBr): 3444, 3073, 1653, 1586, 1455, 1202, 1167, 997, 806, 667 cm-1.
595
Anal. Calcd. for C16H14BrN3S: C, 53.34; H, 3.92; N, 11.66; S, 8.90; found: C, 53.36; H, 3.95;
596
N, 11.69; S, 8.94. HR-MS (ESI+): m/z [M + H] + Calcd. for C16H14BrN3S: 359.00918; found:
597
359.00921.
SC
RI PT
590
599
M AN U
598
4.5.26. 5-Bromo-4-(4-bromophenyl)-N-(3-methylpyridin-2-yl)thiazol-2-amine (8g) White solid from EtOH (87% yield). m.p. 286.9-288.1 °C; 1H NMR (400 MHz,
601
DMSO-d6): δ 11.34 (s, 1H), 8.01 (d, J = 8.9 Hz, 1H), 7.76 (d, J = 8.6 Hz, 2H), 7.56 (d, J =
602
8.6 Hz, 2H), 7.26 (d, J = 10.9 Hz, 1H), 6.62 (t, J = 8.9 Hz, 1H), 2.30 (s, 1H); 13C NMR (101
603
MHz, DMSO-d6) δ 164.05, 161.00, 152.38, 144.08, 136.59, 132.15, 132.03, 128.93, 123.85,
604
118.76, 112.83, 93.34, 16.79; IR (KBr): 3439, 3072, 1653, 1588, 1453, 1211, 1165, 985, 811,
605
655 cm-1. Anal. Calcd. for C15H11Br2N3S: C, 42.38; H, 2.61; N, 9.88; S, 7.54; found: C,
606
42.39; H, 2.66; N, 9.91; S, 7.56. HR-MS (ESI+): m/z [M + H]
607
424.90200; found: 424.9023.
608
610
Calcd. for C15H11Br2N3S:
4.5.27. 4-(3,4-Dichlorophenyl)-N-(6-methylpyridin-2-yl)thiazol-2-amine (8h) White solid from EtOH (94% yield). m.p. 281.3-282 °C; 1H NMR (400 MHz, DMSO-
AC C
609
+
EP
TE D
600
611
d6): δ 11.91 (s, 1H), 8.60 (d, J = 3.8 Hz, 1H), 8.05 (d, J = 7.8 Hz, 1H), 7.86 (t, J = 7.3 Hz,
612
1H), 7.57 (s, 1H), 7.46 – 7.32 (m, 1H), 7.14 (d, J = 7.1 Hz, 1H), 6.96 (d, J = 2.7 Hz, 1H),
613
2.52 (S, 1H);
614
133.74, 132.05, 129.50, 127.52, 126.67, 120.18, 107.19, 104.92, 21.58; IR (KBr): 3385,
615
3075, 2857, 1631, 1585, 1452,1392, 1314, 1260, 1188,1071, 1003, 910, 832, 784 cm-1. Anal.
616
Calcd. for C15H11Cl2N3S: C, 53.58; H, 3.30; N, 12.50; S, 9.54; found: C, 53.60; H, 3.34; N,
617
12.53; S, 9.55. HR-MS (ESI+): m/z [M + H] + Calcd. for C15H11Cl2N3S: 335.00507; found:
618
335.00510.
13
C NMR (101 MHz, DMSO-d6) δ 160.86, 155.20, 153.22, 150.11, 138.26,
619 19
ACCEPTED MANUSCRIPT 620
4.5.28. 4-(4-Bromophenyl)-5-methyl-N-(6-methylpyridin-2-yl)thiazol-2-amine (8i)
621
White solid from EtOH (93% yield). m.p. 282.1-282.9 °C; 1H NMR (400 MHz,
622
DMSO-d6): δ 11.91 (s, 1H), 8.60 (d, J = 3.8 Hz, 1H), 7.87 (d, J = 7.3 Hz, 1H), 7.40 (t, J =
623
7.3, 1H), 6.92 (d, J = 6.3 Hz, 1H), 6.59 (d, J = 8.4 Hz, 1H), 2.50 (s, 4H), 2.40 (s, 3H);
624
NMR (101 MHz, DMSO-d6) δ 162.26, 158.31, 153.22, 148.99, 137.41, 132.31, 131.19,
625
128.38, 123.01, 119.89, 117.63, 103.52, 24.41, 13.97; IR (KBr): 3519, 3074, 1658, 1584,
626
1216, 1168, 987, 821, 643 cm-1. Anal. Calcd. for C16H14BrN3S: C, 53.34; H, 3.92; N, 11.66;
627
S, 8.90; found: C, 53.36; H, 3.89; N, 11.69; S, 8.92. HR-MS (ESI+): m/z [M + H] + Calcd. for
628
C16H14BrN3S: 359.00918; found: 359.00920.
RI PT
C
SC
629 630
13
4.5.29. 4-(4-Methoxyphenyl)-N-(6-methylpyridin-2-yl)thiazol-2-amine (8j) Antique white solid from EtOH (89% yield). m.p. 221.5-222.5 °C; 1H NMR (400
632
MHz, CDCl3 + DMSO-d6): δ 7.89 (s, 1H), 7.68 (d, J = 8.7 Hz, 2H), 7.29 (d, J = 7.1 Hz, 1H),
633
7.18 (s, 1H), 7.05 (d, J = 7.3 Hz, 1H), 6.92 (d, J = 8.8 Hz, 2H), 4.39 (s, 1H), 3.77 (s, 4H),
634
2.64 (s, 3H);
635
136.96, 129.23, 126.17, 116.70, 113.28, 109.67, 103.86, 54.20, 22.47; IR (KBr): 3518, 3068,
636
1644, 1580, 1454, 1256, 1172, 1029, 799 cm-1. Anal. Calcd. for C16H15N3OS, C, 64.62; H,
637
5.08; N, 14.13; S, 10.78; found: C, 64.65; H, 5.10; N, 14.17; S, 10.81. HR-MS (ESI+): m/z
638
[M + H] + Calcd. for C16H15N3OS: 297.09358; found: 297.09361.
640
13
C NMR (101 MHz, CDCl3 + DMSO-d6): δ 163.65, 159.06, 157.67, 150.31,
TE D
639
M AN U
631
4.5.30. N-(6-Methylpyridin-2-yl)-4-(naphthalen-1-yl)thiazol-2-amine (8k) White Solid from EtOH (94% yield). m.p. 227.5-228.4 °C; 1H NMR (400 MHz,
642
DMSO-d6): δ 11.68 (s, 1H), 8.42 (s, 1H), 8.04 (dd, J = 8.6, 1.7 Hz, 1H), 7.99 – 7.86 (m, 2H),
643
7.69 – 7.45 (m, 2H), 7.02 – 6.77 (m, 1H), 2.47 (s, 1H).
644
158.36, 155.05, 150.37, 145.25, 138.56, 128.23, 127.73, 127.55, 127.07, 126.52, 125.63,
645
115.48, 107.56, 94.97, 23.16; IR (KBr): 3057, 3028, 2703, 1649, 1590, 1457, 1170, 885, 784,
646
746 cm-1. Anal. Calcd. for C19H15N3S: C, 71.90; H, 4.76; N, 13.24; S, 10.1; found: 1 C,
647
71.92; H, 4.79; N, 13.28; S, 10.12. HR-MS (ESI+): m/z [M + H]
648
317.09867; found: 317.09872.
13
C NMR (101 MHz, DMSO-d6): δ
AC C
EP
641
+
Calcd. for C19H15N3S:
649 650
4.5.31. N-(Pyridin-2-yl)-4-(pyridin-3-yl)thiazol-2-amine (8l)
651
Antique white solid from EtOH (94% yield). m.p. 235.6-237.6 °C; 1H NMR (400
652
MHz, DMSO-d6): δ 11.48 (s, 1H), 9.14 (s, 1H), 8.51 (d, J = 3.9 Hz, 1H), 8.32 (dd, J = 5.0,
653
1.0 Hz, 1H), 8.28 – 8.21 (m, 1H), 7.72 (ddd, J = 8.8, 7.3, 1.8 Hz, 1H), 7.61 (s, 1H), 7.11 (d, J 20
ACCEPTED MANUSCRIPT 13
C NMR (101 MHz, DMSO-d6): δ 160.01,
654
= 8.3 Hz, 1H), 6.94 (dd, J = 6.4, 5.2 Hz, 1H);
655
151.70, 148.19, 146.78, 146.43, 137.97, 132.79, 123.79, 116.12, 110.86, 107.53; IR (KBr):
656
3241, 3097, 2913, 1621, 1547, 1483, 1404, 1311, 765, 715 cm-1. Anal. Calcd. for C13H10N4S:
657
C, 61.40; H, 3.96; N, 22.03; S, 12.61; found: C, 61.43; H, 3.99; N, 22.07; S, 12.62. HR-MS
658
(ESI+): m/z [M + H] + Calcd. for C13H10N4S: 254.06262; found: 254.06266.
660
RI PT
659
4.5.32. N-(3-Methylpyridin-2-yl)-4-(pyridin-3-yl)thiazol-2-amine (8m)
661
Yellow solid from EtOH (89% yield). m.p. 160.2-161.4 °C; 1H NMR (400 MHz,
662
DMSO-d6): δ 10.54 (s, 1H), 9.16 (d, J = 1.7 Hz, 1H), 8.49 (dd, J = 4.7, 1.5 Hz, 1H), 8.28 –
663
8.23 (m, 1H), 8.18 (dd, J = 4.9, 1.1 Hz, 1H), 7.60 (s, 1H), 7.57 – 7.52 (m, 1H), 7.43 (ddd, J =
664
8.0, 4.8, 0.7 Hz, 1H), 6.90 (dd, J = 7.2, 5.0 Hz, 1H), 2.35 (s, 3H);
665
CDCl3): δ 160.56, 149.64, 148.56, 147.57, 146.41, 144.29, 138.31, 133.19, 130.79, 123.55,
666
117.84, 116.66, 107.51, 16.67; IR (KBr): 3219, 3102, 2921, 1591, 1463, 1189, 811, 781, 731
667
cm-1.. Anal. Calcd. for C14H12N4S C, 62.66; H, 4.51; N, 20.88; S, 11.9; found: 5 C, 62.68; H,
668
4.53; N, 20.94; S, 11.98. HR-MS (ESI+): m/z [M + H]
669
found: 268.07831.
SC
C NMR (101 MHz,
M AN U
670 671
13
+
Calcd. for C14H12N4S: 268.07827;
4.5.33. N-(6-Methylpyridin-2-yl)-4-(pyridin-4-yl)thiazol-2-amine (8n) Yellow solid from EtOH (94% yield). m.p. 294.5-295.4 °C; 1H NMR (400 MHz,
673
DMSO-d6): δ 11.62 (s, 1H), 8.93 (d, J = 6.9 Hz, 1H), 8.42 (d, J = 6.8 Hz, 1H), 8.40 (s, 1H),
674
7.67 – 7.61 (m, 1H), 6.93 (d, J = 8.2 Hz, 1H), 6.84 (d, J = 7.3 Hz, 1H), 2.48 (s, 1H);
675
NMR (101 MHz, DMSO-d6): δ 166.66, 160.71, 155.13, 150.52, 143.66, 142.25, 138.58,
676
122.01, 118.20, 115.59, 107.68, 23.24; IR (KBr): 3211, 3187, 3093, 2729, 1629, 1604, 1541,
677
1463, 1323, 1199, 828, 777 cm-1. Anal. Calcd. for C14H12N4S: C, 62.66; H, 4.51; N, 20.88; S,
678
11.95; found: C, 62.67; H, 4.55; N, 20.94; S, 11.98. HR-MS (ESI+): m/z [M + H] + Calcd. for
679
C14H12N4S: 268.07827; found: 268.07829.
681
13
EP
C
AC C
680
TE D
672
4.5.34. N-(3-Methylpyridin-2-yl)-4-(pyridin-4-yl)thiazol-2-amine (8o)
682
Yellow solid from EtOH (88% yield). m.p. 314.5-315.9 °C; 1H NMR (400 MHz,
683
DMSO-d6): δ 11.15 (s, 1H), 8.98 (d, J = 6.6 Hz, 2H), 8.55 (d, J = 6.6 Hz, 2H), 8.51 (s, 1H),
684
8.28 (d, J = 6.7 Hz, 1H), 7.73 (d, J = 6.7 Hz, 1H), 7.10 – 7.01 (t, J = 6.7 Hz, 1H); 13C NMR
685
(101 MHz, DMSO-d6) δ 161.98, 157.74, 148.99, 145.60, 140.78, 137.69, 136.56, 123.85,
686
116.80, 113.12, 108.88, 40.15, 39.94, 39.74, 39.53, 39.32, 39.11, 38.90, 16.22; IR (KBr):
687
3472, 3390, 3079, 1635, 1581, 1530, 1499, 1458, 1373, 1256, 1190, 827, 790, 670 cm-1. 21
ACCEPTED MANUSCRIPT 688
Anal. Calcd. for C14H12N4S: C, 62.66; H, 4.51; N, 20.88; S, 11.95; found: C, 62.67; H, 4.55;
689
N, 20.94; S, 11.98. HR-MS (ESI+): m/z [M + H] + Calcd. for C14H12N4S: 268.07827; found:
690
268.07829.
691
4.6.
In vitro assay for evaluation of antimycobacterial activity
RI PT
692
The in vitro assay method previously reported by our group has been used for
694
evaluation of antimycobacterial assay. DMSO was used for the preparation of the test
695
compound stocks as well as for dilutions. The test compounds MICs against Mtb were
696
analysed in 7H9 broth using a standard micro dilution method [61]. The test compounds
697
which were prepared with 1µl of serial twofold dilutions in DMSO were added in to the 384
698
well plates with the final concentrations ranging from 100 mM - 0.19 mM. Two sets of
699
control wells were prepared: a media control with only medium (Middlebrook 7H9 medium
700
supplemented with 0.2% glycerol, 0.05% Tween 80 (Sigma), and 10% albumin dextrose
701
catalase (Difco Laboratories, Detroit, Mich.)) and a culture control with a bacterial
702
suspension but no compound. 40µl (3-7 x 105 CFU/ml) of the bacterial culture was added to
703
all the wells except the media control wells. The plates were packed in gas permeable
704
polythene bags and incubated at 37°C for 5 days. Following this incubation period, 8 µl of a
705
freshly prepared 1:1 mixture of Resazurin (0.02% in water) and 10% Tween 80 was added to
706
all the wells. The plates were re-incubated for an additional 24 h at 37°C and the colour
707
conversion of all wells recorded. A blue colour in the well indicates no growth and a pink
708
colour indicates growth. Absorbance at 575 nm and 610 nm was monitored and the ratio
709
(A575/A610) calculated. The least concentration which yielded 80% inhibition was considered
710
as MIC; the media control is considered 100% inhibition and the culture control as 0%
711
inhibition. Isoniazid was used as a reference drug for the assay.
712
4. 7.
M AN U
TE D
EP
AC C
713
SC
693
Molecular docking studies
The docking simulations were performed using Auto Dock 4.2 [62]. The recently
714
solved X-ray crystal structure of KasA of Mtb (PDB code: 2WGD) in complex with TLM has
715
been retrieved from the RCSB Protein Data Bank and all heteroatoms were removed. The
716
2WGD was setup for a standard protocol for docking. Lamarckian Genetic Algorithm was
717
used to carry out the simulation. Columbic electrostatic potential, Vander Waals interaction
718
represented as a Lennard-Jones12–6 dispersion/repulsion term and hydrogen bonding 22
ACCEPTED MANUSCRIPT represented as a directional 12–10 term were the three parameters taken into account for
720
evaluating binding energy in the docking step. The most favourable free energy of binding
721
were attained by considering the docking orientations lying within the range of 2.0 Å in the
722
root-mean square deviation (rmsd) tolerance and clustering the each other to get the result.
723
The post-docking energy minimization on Discovery Studio 2.5 was performed on top-posed
724
docking conformations obtained.
725
Acknowledgements
RI PT
719
We are grateful to AstraZeneca India Pvt. Ltd., Bangalore, India for generation of the
726
MIC data against Mtb. The authors thank Council of Scientific and Industrial Research
728
(CSIR), New Delhi, India for financial support through a sponsored project (01 (2262)
729
/08/EMR-II). Mr. Parameshwar Makam thanks Pondicherry University for awarding
730
University Research Fellowship (URF).
731
Appendix A. Supplementary information
M AN U
SC
727
Supplementary information related to this article can be found at…
732 733
References
734
[1]
TE D
Tuberculosis: WHO global tuberculosis report 2013, in, World Health Organization, World Health Organization, Geneva, 2013.
735
[2]
H. Herzog, History of tuberculosis, Respiration 65 (1998) 5-15.
737
[3]
C. Lienhardt, S.V. Cook, M. Burgos, V.Y. Edwards, L. Rigouts, G. Anyo, K.S. Jae,
EP
736
A. Jindani, D.A. Enarson, A.J. Nunn, Efficacy and safety of a 4-drug fixed-dose
739
combination regimen compared with separate drugs for treatment of pulmonary
740
tuberculosis: The study c randomized controlled trial, JAMA 305 (2011) 1415-1423.
741
[4]
359 (2002) 2188-2194.
743
[5]
[6]
749
R. Osborne, First novel anti-tuberculosis drug in 40 years, Nat. Biotech. 31 (2013) 8991.
747 748
M.R. Ward, Notes on the 2004 to 2009 United States Food and Drug Administration approval of new molecular entities (NMEs), in: KEI Research Note, 2010, pp. 1-14.
745 746
P. Trouiller, P. Olliaro, E. Torreele, J. Orbinski, R. Laing, N. Ford, Drug development for neglected diseases: A deficient market and a public-health policy failure, Lancet
742
744
AC C
738
[7]
A. Zumla, P. Nahid, S.T. Cole, Advances in the development of new tuberculosis drugs and treatment regimens, Nat. Rev. Drug Discov. 12 (2013) 388-404. 23
ACCEPTED MANUSCRIPT 750
[8]
Microbiol. Rev. 24 (2011) 351-376.
751 752
[9]
Z.F. Udwadia, R.A. Amale, K.K. Ajbani, C. Rodrigues, Totally drug-resistant tuberculosis in India, Clin. Infect. Dis. 54 (2012) 579-581.
753 754
C.K. Kwan, J.D. Ernst, HIV and tuberculosis: A deadly human syndemic, Clin.
[10]
M. Zignol, M. S.Hosseini, A. Wright, C.L.V. Weezenbeek, P. Nunn, C.J. Watt, B.G. Williams, C. Dye, Global incidence of multidrug-resistant tuberculosis, J. Infect. Dis.
756
194 (2006) 479-485.
757
[11]
RI PT
755
N.R. Gandhi, A. Moll, A.W. Sturm, R. Pawinski, T. Govender, U. Lalloo, K. Zeller, J. Andrews, G. Friedland, Extensively drug-resistant tuberculosis as a cause of death in
759
patients co-infected with tuberculosis and HIV in a rural area of South Africa, Lancet
760
368 (2006) 1575-1580. [12]
S.E. Dorman, R.E. Chaisson, From magic bullets back to the magic mountain: The rise of extensively drug-resistant tuberculosis, Nat. Med. 13 (2007) 295-298.
762
M AN U
761
SC
758
763
[13]
C. Dye, Global epidemiology of tuberculosis, Lancet 367 (2006) 938-940.
764
[14]
C.U. Köser, J.M. Bryant, J. Becq, M.E. Török, M.J. Ellington, M.A. Marti-Renom,
765
A.J. Carmichael, J. Parkhill, G.P. Smith, S.J. Peacock, Whole-genome sequencing for
766
rapid susceptibility testing of M. tuberculosis, New Engl. J. Med. 369 (2013) 290-292. [15]
M.R. Farhat, B.J. Shapiro, K.J. Kieser, R. Sultana, K.R. Jacobson, T.C. Victor, R.M.
TE D
767
Warren, E.M. Streicher, A. Calver, A. Sloutsky, D. Kaur, J.E. Posey, B. Plikaytis,
769
M.R. Oggioni, J.L. Gardy, J.C. Johnston, M. Rodrigues, P.K.C. Tang, M. Kato-
770
Maeda, M.L. Borowsky, B. Muddukrishna, B.N. Kreiswirth, N. Kurepina, J. Galagan,
771
S. Gagneux, B. Birren, E.J. Rubin, E.S. Lander, P.C. Sabeti, M. Murray, Genomic
772
analysis identifies targets of convergent positive selection in drug-resistant
773
Mycobacterium tuberculosis, Nat. Genet. 45 (2013) 1183-1189. [16]
AC C
774
EP
768
H. Zhang, D. Li, L. Zhao, J. Fleming, N. Lin, T. Wang, Z. Liu, C. Li, N. Galwey, J.
Deng, Y. Zhou, Y. Zhu, Y. Gao, T. Wang, S. Wang, Y. Huang, M. Wang, Q. Zhong,
775
L. Zhou, T. Chen, J. Zhou, R. Yang, G. Zhu, H. Hang, J. Zhang, F. Li, K. Wan, J.
776
Wang, X.-E. Zhang, L. Bi, Genome sequencing of 161 Mycobacterium tuberculosis
777 778
isolates from China identifies genes and intergenic regions associated with drug
779
resistance, Nat. Genet. 45 (2013) 1255-1260.
780
[17]
S. Ananthan, E.R. Faaleolea, R.C. Goldman, J.V. Hobrath, C.D. Kwong, B.E.
781
Laughon, J.A. Maddry, A. Mehta, L. Rasmussen, R.C. Reynolds, J.A. Secrist, 3rd, N.
782
Shindo, D.N. Showe, M.I. Sosa, W.J. Suling, E.L. White, High-throughput screening
783
for inhibitors of Mycobacterium tuberculosis H37Rv, Tuberculosis 89 (2009) 334-353. 24
ACCEPTED MANUSCRIPT 784
[18]
R.C. Reynolds, S. Ananthan, E. Faaleolea, J.V. Hobrath, C.D. Kwong, C. Maddox, L.
785
Rasmussen, M.I. Sosa, E. Thammasuvimol, E.L. White, W. Zhang, J.A. Secrist Iii,
786
High throughput screening of a library based on kinase inhibitor scaffolds against
787
Mycobacterium tuberculosis H37Rv, Tuberculosis 92 (2012) 72-83. [19]
development, J. Med. Chem. 54 (2011) 6157-6165.
789 790
[20]
A. Koul, E. Arnoult, N. Lounis, J. Guillemont, K. Andries, The challenge of new drug discovery for tuberculosis, Nature 469 (2011) 483-490.
791 792
L.G. Dover, G.D. Coxon, Current status and research strategies in tuberculosis drug
[21]
RI PT
788
M. Pieroni, B. Wan, S. Cho, S.G. Franzblau, G. Costantino, Design, synthesis and investigation on the structure–activity relationships of N-substituted 2-aminothiazole
794
derivatives as antitubercular agents, Eur. J. Med. Chem. 72 (2014) 26-34.
795
[22]
SC
793
A. Meissner, H.I. Boshoff, M. Vasan, B.P. Duckworth, C.E. Barry Iii, C.C. Aldrich, Structure–activity relationships of 2-aminothiazoles effective against Mycobacterium
797
tuberculosis, Bioorg. Med. Chem. 21 (2013) 6385-6397.
798
[23]
M AN U
796
G. Pappenberger, T. Schulz-Gasch, E. Kusznir, F. Muller, M. Hennig, Structureassisted discovery of an aminothiazole derivative as a lead molecule for inhibition of
800
bacterial fatty-acid synthesis, Acta Crystallogr., Sect. D: Biol. Crystallogr. 63 (2007)
801
1208-1216.
802
[24]
TE D
799
S.R. Luckner, C.A. Machutta, P.J. Tonge, C. Kisker, Crystal structures of
803
Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis
804
and its inhibition by thiolactomycin, Structure 17 (2009) 1004-1013. [25]
Q. Al-Balas, N.G. Anthony, B. Al-Jaidi, A. Alnimr, G. Abbott, A.K. Brown, R.C.
EP
805
Taylor, G.S. Besra, T.D. McHugh, S.H. Gillespie, B.F. Johnston, S.P. Mackay, G.D.
807
Coxon, Identification of 2-aminothiazole-4-carboxylate derivatives active against Mycobacterium tuberculosis H37Rv and the β-ketoacyl-ACP synthase MtfabH, PloS
808
one 4 (2009) e5617.
809 810
[26]
E.C. Dykhuizen, J.F. May, A. Tongpenyai, L.L. Kiessling, Inhibitors of UDP-
Galactopyranose mutase thwart mycobacterial growth, J. Am. Chem. Soc. 130 (2008)
811
6706-6707.
812 813
AC C
806
[27]
L.P.S. de Carvalho, G. Lin, X. Jiang, C. Nathan, Nitazoxanide kills replicating and
814
nonreplicating Mycobacterium tuberculosis and evades resistance, J. Med. Chem. 52
815
(2009) 5789-5792.
816 817
[28]
L.M. Fox, L.D. Saravolatz, Nitazoxanide: A new thiazolide antiparasitic agent, Clin. Infect. Dis. 40 (2005) 1173-1180. 25
ACCEPTED MANUSCRIPT 818
[29]
imidazo[2,1-b]thiazole derivatives, Eur. J. Med. Chem. 42 (2007) 320-326.
819 820
[30]
J. Araujo, C. Logothetis, Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors, Cancer Treat. Rev. 36 (2010) 492-500.
821 822
E. Gürsoy, N.U. Güzeldemirci, Synthesis and primary cytotoxicity evaluation of new
[31]
W.C. Patt, H.W. Hamilton, M.D. Taylor, M.J. Ryan, D.G. Taylor, C.J.C. Connolly, A.M. Doherty, S.R. Klutchko, I. Sircar, Structure-activity relationships of a series of
824
2-amino-4-thiazole-containing renin inhibitors, J. Med. Chem. 35 (1992) 2562-2572.
825
[32]
RI PT
823
O. Kouatly, A. Geronikaki, C. Kamoutsis, D. Hadjipavlou-Litina, P. Eleftheriou,
Adamantane derivatives of thiazolyl-N-substituted amide, as possible non-steroidal
827
anti-inflammatory agents, Eur. J. Med. Chem. 44 (2009) 1198-1204.
828
[33]
SC
826
J.S. Carter, D.J. Rogier, M.J. Graneto, K. Seibert, C.M. Koboldt, Z. Yan, J.J. Talley, Design and synthesis of sulfonyl-substituted 4,5-diarylthiazoles as selective
830
cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 9 (1999) 1167-1170.
831
[34]
M AN U
829
N. Ergenç, G. Çapan, N.S. Günay, S. Özkirimli, M. Güngör, S. Özbey, E. Kendi,
832
Synthesis and hypnotic activity of new 4-thiazolidinone and 2-thioxo-4,5-
833
imidazolidinedione derivatives, Arch. Pharm. 332 (1999) 343-347.
834
[35]
J.C. Jaen, L.D. Wise, B.W. Caprathe, H. Tecle, S. Bergmeier, C.C. Humblet, T.G. Heffner, L.T. Meltzer, T.A. Pugsley, 4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-
836
thiazolamines: A novel class of compounds with central dopamine agonist properties,
837
J. Med. Chem. 33 (1990) 311-317.
838
[36]
TE D
835
N. Masuda, O. Yamamoto, M. Fujii, T. Ohgami, J. Fujiyasu, T. Kontani, A. Moritomo, M. Orita, H. Kurihara, H. Koga, H. Nakahara, S. Kageyama, M. Ohta, H.
840
Inoue, T. Hatta, H. Suzuki, K. Sudo, Y. Shimizu, E. Kodama, M. Matsuoka, M.
841
Fujiwara, T. Yokota, S. Shigeta, M. Baba, Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of
842
thiazolidenebenzenesulfonamides, Bioorg. Med. Chem. 12 (2004) 6171-6182.
843 844
[37]
H. Karade, B.N. Acharya, M. Sathe, M.P. Kaushik, Design, synthesis, and
antimalarial evaluation of thiazole-derived amino acids, Med. Chem. Res. 17 (2008)
845
19-29.
846 847
AC C
EP
839
[38]
D. González Cabrera, F. Douelle, T.-S. Feng, A.T. Nchinda, Y. Younis, K.L. White,
848
Q. Wu, E. Ryan, J.N. Burrows, D. Waterson, M.J. Witty, S. Wittlin, S.A. Charman, K.
849
Chibale, Novel orally active antimalarial thiazoles, J. Med. Chem. 54 (2011) 7713-
850
7719.
26
ACCEPTED MANUSCRIPT 851
[39]
N.U. Güzeldemirci, Ö. Küçükbasmacı, Synthesis and antimicrobial activity evaluation
852
of new 1,2,4-triazoles and 1,3,4-thiadiazoles bearing imidazo[2,1-b]thiazole moiety,
853
Eur. J. Med. Chem. 45 (2010) 63-68.
854
[40]
P. Makam, R. Kankanala, A. Prakash, T. Kannan, 2-(2-Hydrazinyl)thiazole derivatives: Design, synthesis and in vitro antimycobacterial studies, Eur. J. Med.
856
Chem. 69 (2013) 564-567.
857
[41]
P. Makam, P.K. Thakur, T. Kannan, In vitro and in silico antimalarial activity of 2-(2hydrazinyl)thiazole derivatives, Eur. J. Pharm. Sci. 52 (2014) 138-145.
858 859
RI PT
855
[42]
M.P. Gleeson, A. Hersey, D. Montanari, J. Overington, Probing the links between in vitro potency, ADMET and physicochemical parameters, Nat. Rev. Drug Discov. 10
861
(2011) 197-208.
862
[43]
SC
860
S. Khojasteh, H. Wong, C.C.A. Hop, ADME properties and their dependence on physicochemical properties, in: Drug metabolism and pharmacokinetics quick guide,
864
Springer New York, 2011, pp. 165-181.
865
[44]
M AN U
863
C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and
866
computational approaches to estimate solubility and permeability in drug discovery
867
and development settings, Adv. Drug Deliver. Rev. 46 (2001) 3-26. [45]
D.F. Veber, S.R. Johnson, H.-Y. Cheng, B.R. Smith, K.W. Ward, K.D. Kopple,
TE D
868 869
Molecular properties that influence the oral bioavailability of drug candidates, J. Med.
870
Chem. 45 (2002) 2615-2623. [46]
[47]
[48]
Discovery Des. 19 (2000) 179-211.
877
[49]
The influence of lipophilicity in drug discovery and design, Expert Opin. Drug
Discov. 7 (2012) 863-875.
879 880
B. Testa, P. Crivori, M. Reist, P.-A. Carrupt, The influence of lipophilicity on the
pharmacokinetic behavior of drugs: Concepts and examples, Perspect. Drug
876
878
Á. Tarcsay, K. Nyíri, G.M. Keserű, Impact of lipophilic efficiency on compound quality, J. Med. Chem. 55 (2012) 1252-1260.
874 875
EP
making in medicinal chemistry, Nat. Rev. Drug Discov. 6 (2007) 881-890.
872 873
P.D. Leeson, B. Springthorpe, The influence of drug-like concepts on decision-
AC C
871
[50]
N. Siddiqui, W. Ahsan, Triazole incorporated thiazoles as a new class of
881
anticonvulsants: Design, synthesis and in vivo screening, Eur. J. Med. Chem. 45
882
(2010) 1536-1543.
883 884
[51]
M.P. Hay, S. Turcotte, J.U. Flanagan, M. Bonnet, D.A. Chan, P.D. Sutphin, P. Nguyen, A.J. Giaccia, W.A. Denny, 4-Pyridylanilinothiazoles that selectively target 27
ACCEPTED MANUSCRIPT 885
von Hippel−Lindau deficient renal cell carcinoma cells by inducing autophagic cell
886
death, J. Med. Chem. 53 (2009) 787-797.
887
[52]
A. Gallardo-Godoy, J. Gever, K.L. Fife, B.M. Silber, S.B. Prusiner, A.R. Renslo, 2-
888
Aminothiazoles as therapeutic leads for prion diseases, J. Med. Chem. 54 (2011)
889
1010-1021. [53]
K. Jain, J. Bariwal, M. Kathiravan, V. Raskar, G. Wankhede, N. Londhe, An efficient
RI PT
890 891
and rapid synthesis of 2-amino-4-arylthiazoles employing microwave irradiation in
892
water, Green and Sustainable Chem. 1 (2011) 36-40 [54]
arylthiazole derivatives, Asian J. Res. Chem. 2 (2009) 440-444.
894 895
R. Basawaraj, M. Shabbir, Synthesis and biological screening of some new series of
[55]
SC
893
M.G. Bursavich, D.P. Parker, J.A. Willardsen, Z.-H. Gao, T. Davis, K. Ostanin, R. Robinson, A. Peterson, D.M. Cimbora, J.-F. Zhu, B. Richards, 2-Anilino-4-aryl-1,3-
897
thiazole inhibitors of valosin-containing protein (VCP or p97), Bioorg. Med. Chem.
898
Lett. 20 (2010) 1677-1679.
899
[56]
M AN U
896
A.K. Sharma, U.H. Sk, M.A. Gimbor, J.A. Hengst, X. Wang, J. Yun, S. Amin,
900
Synthesis and bioactivity of sphingosine kinase inhibitors and their novel aspirinyl
901
conjugated analogs, Eur. J. Med. Chem. 45 (2010) 4149-4156. [57]
R.G. Gentles, K. Grant-Young, S. Hu, Y. Huang, M.A. Poss, C. Andres, T. Fiedler, R.
TE D
902 903
Knox, N. Lodge, C.D. Weaver, D.G. Harden, Initial SAR studies on apamin-
904
displacing 2-aminothiazole blockers of calcium-activated small conductance
905
potassium channels, Bioorg. Med. Chem. Lett. 18 (2008) 5316-5319. [58]
B.M. Silber, S. Rao, K. Fife, A. Gallardo-Godoy, A. Renslo, D. Dalvie, K. Giles, Y.
EP
906
Freyman, M. Elepano, J. Gever, Z. Li, M. Jacobson, Y. Huang, L. Benet, S. Prusiner,
908
Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice, Pharmaceut. Res. 30 (2013) 932-950.
909 910
[59]
C. Pascard, Small-molecule crystal structures as a structural basis for drug design,
Acta Crystallogr., Sect. D: Biol. Crystallogr. 51 (1995) 407-417.
911 912
AC C
907
[60]
K.A. Brameld, B. Kuhn, D.C. Reuter, M. Stahl, Small molecule conformational
913
preferences derived from crystal structure data. A medicinal chemistry focused
914
analysis, J. Chem. Inf. Model. 48 (2008) 1-24.
915
[61]
M. Balganesh, S. Kuruppath, N. Marcel, S. Sharma, A. Nair, U. Sharma, Rv1218c, an
916
ABC transporter of Mycobacterium tuberculosis with implications in drug discovery,
917
Antimicrob. Agents Chemother. 54 (2010) 5167-5172.
28
ACCEPTED MANUSCRIPT 918
[62]
G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, A.J.
919
Olson, AutoDock 4 and AutoDockTools 4: Automated docking with selective
920
receptor flexibility, J. Comput. Chem. 30 (2009) 2785-2791.
921
AC C
EP
TE D
M AN U
SC
RI PT
922
29
ACCEPTED MANUSCRIPT 923
Figure and Scheme Legends
924
Figure 1. Rational design of the 2-aminothiazole derivatives. Log P is considered as the
926
decisive factor.
927
Figure 2. Single crystal X-ray diffraction results of 7g. (a) The ORTEP diagram with 40%
928
ellipsoid probability (b) The crystal packing diagram along the c-axis and (c) The single helix
929
packing arrangement along the a-axis.
930
Figure 3. Single crystal X-ray diffraction results of 8l. (a) The ORTEP diagram with 40%
931
ellipsoid probability (b) The crystal packing diagram along the a-axis and (c) The single helix
932
packing arrangement along the b-axis.
933
Figure 4. The summary of structure activity relationship studies.
934
Figure 5. The summary of correlation between Log P and in vitro antimycobacterial activity.
935
Figure 6. Hydrogen bond interactions of compound 7n with Mtb KasA protein.
936
Scheme 1. Synthesis of (i) arylthioureas (ii) pyridyl thioureas (iii) (bromoacetyl)pyridines
937
and (iv) 2-aminothiazole derivatives.
AC C
EP
TE D
M AN U
SC
RI PT
925
30
ACCEPTED MANUSCRIPT Table 1. Physico-chemical properties a and antimycobacterial activity of thiazol-2-amine derivatives against Mtb, H37Rv. S. No. Compound Log P H Freely MIC Mol. H Lipinski Polar Weight rule Acceptors Donors Rotatable Surface (µM) violations Area Bonds 1 5.70 349.228 2 1 1 3 24.919 12.5 7a 7b
6.35
363.255
2
1
1
3
7c
6.64
428.124
2
1
1
4
7d
5.54
304.777
2
1
1
5
7e
5.09
302.786
3
2
0
6
7f
4.77
300.358
3
1
7
7g
4.33
298.367
4
2
8
7h
6.48
361.803
5
1
9
7i
5.92
320.392
2
10
7j
7.62
381.835
11
7k
5.80
332.764
12
7l
3.71
271.32
13
7m
4.34
332.226
14
7n
3.27
15
7o
5.42
16
7p
3.71
17
7q
4.34
18
7r
19
7s
20
8a
21
3
24.919
RI PT
2
25
24.919
100
3
24.919
25
3
45.147
100
0
4
34.153
12.5
0
4
54.381
200
1
5
79.97
>200
1
1
3
24.919
12.5
4
1
1
4
70.74
>200
5
1
1
4
83.63
>200
3
1
0
3
37.811
25
3
1
0
3
37.811
6.25
269.329
4
2
0
3
58.039
>200
332.764
5
1
1
4
83.63
>200
271.32
3
1
0
3
37.811
>200
332.226
3
1
0
3
37.811
>200
M AN U
TE D
AC C
EP
SC
3
3.27
269.329
4
2
0
3
58.039
>200
5.42
332.764
5
1
1
4
83.63
>200
4.01
283.356
4
1
0
4
47.045
>200
8b
4.93
332.226
3
1
0
3
37.811
>200
22
8c
5.58
346.253
3
1
0
3
37.811
>200
23
8d
5.87
411.122
3
1
1
3
37.811
>200
24
8e
2.95
254.318
4
1
0
3
50.703
>200
25
8f
3.46
268.345
4
1
0
3
50.703
100
26
8g
3.46
268.345
4
1
0
3
50.703
>200
27
8h
5.89
336.247
3
1
1
3
37.811
>200
28
8i
6.38
425.149
3
1
1
3
37.811
>200
29
8j
6.09
360.28
3
1
1
3
37.811
>200
30
8k
5.71
360.28
3
1
0
3
37.811
>200
31
8l
4.14
297.383
4
1
0
4
47.045
>200
32
8m
5.51
336.247
3
1
1
3
37.811
>200
33
8n
3.08
268.345
4
1
0
3
50.703
100
34
8o
5.29
317.417
3
1
0
3
37.811
>200
EP
TE D
RI PT
M AN U
SC
Calculated from online server http://www.molinspiration.com/cgi-bin/properties
AC C
a
ACCEPTED MANUSCRIPT
ACCEPTED MANUSCRIPT Table 2. Library of N-phenyl thiazol-2-amine and N-2-pyridyl thiazol-2-amine derivatives. Category I: N,4-Diphenylthiazol-2-amine derivatives
8a
8f
RI PT
SC
M AN U
7p
7d
7g 7h 7i Category II: N-Phenyl-4-(pyridinyl)thiazol-2-amine derivatives
7l
7m
7n
8b
7j
7o
8g
8c
8d
8e
8h
8i
8j
8k Category IV: N,4-Di(pyridinyl)thiazol-2-amine derivatives
8l
7e
7q 7r 7s Category III: 4-Phenyl-N-(pyridinyl)thiazol-2-amine derivatives
TE D
7k
7c
EP
7f
7b
AC C
7a
8m
8n
8o
ACCEPTED MANUSCRIPT Table 3. Crystal and measurement details of 7g and 8l molecules. Crystal Parameter
7g
8l
C15H12.5ClN2OS
C13H10N4S
CCDC Number
903724
903727
Formula weight
624.58
254.32
Crystal system
Monoclinic
Monoclinic
Crystal morphology
Colourless block
Pale Yellow needle
Crystal size (mm)
0.45 × 0.37 × 0.25
0.42 × 0.14 × 0.14
Space group
C2/c
P21/C
Temperature/K
293
293
Radiation, λ
Mo Kα , 0.71073 Å
Mo Kα , 0.71073 Å
a (Å)
31.9952 (16)
14.612 (3)
b (Å)
11.3729 (6)
c (Å)
7.8990 (4)
14.715 (3)
α (Å)
-
90°
β (Å)
93.304 (4)°
104.79 (2)°
γ (Å)
-
90°
Volume (Å3)
2869.5 (3)
SC 5.5299 (11)
M AN U
TE D
Z
RI PT
Formula
1149.6 (4)
4
4
1292
528.0
Density (Mg m−3)
1.446
1.469
µ (1/mm)
0.41
0.27
θ (min, max)
3.2, 25.0°
2.9, 25.0°
No. Unique refln
2538
2032
No. of parameters
194
163
Rint, wR(F2)
0.022, 0.109
0.075, 0.128
∆ρmin(eÅ-3), ∆ρmax(eÅ-3)
−0.47, 0.39
−0.34, 0.33
GooF
1.02
0.96
AC C
EP
F (000)
AC C
EP
TE D
M AN U
SC
RI PT
ACCEPTED MANUSCRIPT
AC C
EP
TE D
M AN U
SC
RI PT
ACCEPTED MANUSCRIPT
AC C
EP
TE D
M AN U
SC
RI PT
ACCEPTED MANUSCRIPT
AC C
EP
TE D
M AN U
SC
RI PT
ACCEPTED MANUSCRIPT
AC C EP TE D
SC
M AN U
RI PT
Figure 5
AC C EP TE D
SC
M AN U
RI PT
Figure 6
AC C
EP
TE D
M AN U
SC
RI PT
ACCEPTED MANUSCRIPT
ACCEPTED MANUSCRIPT
Research Highlights Library of 2-aminothiazole derivatives were synthesized and characterized.
•
All the compounds were evaluated against M. tuberculosis, H37Rv, by in vitro assay.
•
4-Halophenyl at 2nd position of 2-aminothiazole derivatives enhances activity.
•
2-Pyridyl at 2nd position of 2-aminothiazole derivatives decreases activity.
•
The MIC and Ki values of compound 7n are 6.5 µM and 0.44 µM respectively.
AC C
EP
TE D
M AN U
SC
RI PT
•
SPECTRAL ANALYSIS OF
AC C
EP
TE D
M AN U
SC
CATEGORY-I COMPOUNDS
RI PT
ACCEPTED MANUSCRIPT
ACCEPTED MANUSCRIPT
M AN U
SC
RI PT
7a: 1H NMR (400 MHz, CDCl3) δ
AC C
EP
TE D
7a: 13C NMR (101 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
7b: 13C NMR (101 MHz, CDCl3)
M AN U
SC
RI PT
7b: 1H NMR (400 MHz, CDCl3) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
7c: 13C NMR (101 MHz, DMSO-d6) δ
M AN U
SC
RI PT
7c: 1H NMR (400 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
7d: 13C NMR (101 MHz, DMSO-d6) δ
M AN U
SC
RI PT
7d: 1H NMR (400 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
7e: 13C NMR (101 MHz, CDCl3) δ
M AN U
SC
RI PT
7e: 1H NMR (400 MHz, CDCl3) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
7f: 13C NMR (101 MHz, CDCl3) δ
M AN U
SC
RI PT
7f: 1H NMR (400 MHz, CDCl3) δ
ACCEPTED MANUSCRIPT
M AN U
SC
RI PT
7g: 1H NMR (400 MHz, DMSO-d6) δ
AC C
EP
TE D
7g: 13C NMR (101 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
7h: 13C NMR (101 MHz, DMSO-d6) δ
M AN U
SC
RI PT
7h: 1H NMR (400 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
M AN U
SC
RI PT
7i: 1H NMR (400 MHz, DMSO-d6) δ
AC C
EP
TE D
7i: 13C NMR (101 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
M AN U
SC
RI PT
7j: 1H NMR (400 MHz, DMSO-d6) δ
AC C
EP
TE D
7j: 13C NMR (101 MHz, DMSO) δ
ACCEPTED MANUSCRIPT
OF
AC C
EP
TE D
M AN U
SC
CATEGORY-II COMPOUNDS
RI PT
SPECTRAL ANALYSIS
ACCEPTED MANUSCRIPT
AC C
EP
TE D
7k: 13C NMR (101 MHz, CDCl3) δ
M AN U
SC
RI PT
7k: 1H NMR (400 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
7l: 13C NMR (101 MHz, DMSO-d6) δ
M AN U
SC
RI PT
7l: 1H NMR (400 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
7m: 13C NMR (101 MHz, DMSO-d6) δ
M AN U
SC
RI PT
7m: 1H NMR (400 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
M AN U
SC
RI PT
7n: 1H NMR (400 MHz, DMSO-d6) δ
AC C
EP
TE D
7n: 13C NMR (101 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
7o: 13C NMR (101 MHz, DMSO-d6) δ
M AN U
SC
RI PT
7o: 1H NMR (400 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
TE D
M AN U
SC
RI PT
7p: 1H NMR (400 MHz, DMSO-d6) δ
AC C
EP
7p: 13C NMR (101 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
7q: 13C NMR (101 MHz, DMSO-d6) δ
M AN U
SC
RI PT
7q: 13C NMR (101 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
7r: 13C NMR (101 MHz, DMSO-d6) δ
M AN U
SC
RI PT
7r: 1H NMR (400 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
TE D
M AN U
SC
RI PT
7s: 1H NMR (400 MHz, DMSO-d6) δ
AC C
EP
7s: 13C NMR (101 MHz, DMSO-d6) δ
SPECTRAL ANALYSIS
SC
OF
RI PT
ACCEPTED MANUSCRIPT
AC C
EP
TE D
M AN U
CATEGORY-III COMPOUNDS
ACCEPTED MANUSCRIPT
AC C
EP
TE D
8a: 13C NMR (101 MHz, DMSO-d6) δ
M AN U
SC
RI PT
8a: 1H NMR (400 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
M AN U
SC
RI PT
8b: 1H NMR (400 MHz, DMSO-d6) δ
AC C
EP
TE D
8b: 13C NMR (101 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
8c: 13C NMR (101 MHz, DMSO-d6) δ
M AN U
SC
RI PT
8c: 1H NMR (400 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
8d: 13C NMR (101 MHz, DMSO-d6) δ
M AN U
SC
RI PT
8d: 1H NMR (400 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
M AN U
SC
RI PT
8e: 1H NMR (400 MHz, DMSO-d6) δ
AC C
EP
TE D
8e: 13C NMR (101 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
8f: 13C NMR (101 MHz, DMSO-d6) δ
M AN U
SC
RI PT
8f: 1H NMR (400 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
8g: 13C NMR (101 MHz, DMSO-d6) δ
M AN U
SC
RI PT
8g: 1H NMR (400 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
8h: 13C NMR (101 MHz, DMSO-d6) δ
M AN U
SC
RI PT
8h: 1H NMR (400 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
8i: 13C NMR (101 MHz, DMSO-d6) δ
M AN U
SC
RI PT
8i: 1H NMR (400 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
TE D
M AN U
SC
RI PT
8j: 1H NMR (400 MHz, CDCl3 + DMSO-d6) δ
AC C
EP
8j: 13C NMR (101 MHz, DMSO-d6 + CDCl3) δ
ACCEPTED MANUSCRIPT
TE D
M AN U
SC
RI PT
8k: 1H NMR (400 MHz, DMSO-d6) δ
AC C
EP
8k: 13C NMR (101 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
8l: 13C NMR (101 MHz, DMSO-d6) δ
M AN U
SC
RI PT
8l: 1H NMR (400 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
8m: 13C NMR (101 MHz, CDCl3) δ
M AN U
SC
RI PT
8m: 1H NMR (400 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
M AN U
SC
RI PT
8n: 1H NMR (400 MHz, DMSO-d6) δ
AC C
EP
TE D
8n: 13C NMR (101 MHz, DMSO-d6) δ
ACCEPTED MANUSCRIPT
AC C
EP
TE D
8o: 13C NMR (101 MHz, DMSO-d6) δ
M AN U
SC
RI PT
8o: 1H NMR (400 MHz, DMSO-d6) δ